2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY BACKGROUND OF THE INVENTION 1. Cross-reference to related application The present application is a continuation-in-part of application serial number 08/466,000, filed on June 6, 1995, to be issued as United 5,675,033<BR> <BR> <BR> States Patent No 5 X 6 7 5, o 3 3 2. Field of the Invention The present invention relates to novel compounds having retinoid-like activity. More specifically, the present invention relates to compounds having a 2,4-pentadienoic acid or 2,4-pentadienoic acid ester function which is substituted in the 5-position with a tetrahydronaphthyl-aryl, chromanyl-aryl, thiochromanyl-aryl, 1,2,3,4-tetrahydroquinolinyl-aryl or with a tetrahydronaphthyl-cycloalkyl, chromanyl-cyclo alkyl, thiochromanyl-cycloalkyl, 1,2,3,4-tetrahydroquinolinyl-cycloalkyl group. The acid function may also be converted to an alcohol, aldehyde or ketone or derivatives thereof, or may be reduced to -CH3, and the tetrahydronaphthyl-aryl, chromanyl-aryl, thiochromanyl-aryl, 1 ,2,3,4-tetrahydroquinolinyl-aryl, tetrahydronaphthyl-cycloalkyl, chromanyl-cycloalkyl, thiochromanyl-cycloalkyl, and 1 ,2,3,4-tetrahydroquinolinyl-cycloalkyl groups may be further substituted with one or more alkyl substituents.

3. Background Art Compounds which have retinoid-like activity are well known in the art, and are described in numerous United States and other patents and in scientific publications. It is generally known and accepted in the art that retinoid-like activity is useful for treating animals of the mammalian species, including humans, for curing or alleviating the symptoms and conditions of numerous diseases and conditions. In other words, it is generally accepted in the art that pharmaceutical

compositions having a retinoid-like compound or compounds as the active ingredient are useful as regulators of cell proliferation and differentiation, and particularly as agents for treating skin-related diseases, including, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hyperproliferative disorders of the skin, eczema, atopic dermatitis, Darriers disease, lichen planus, prevention and reversal of glucocorticoid damage (steroid atrophy), as a topical anti-microbial, as skin anti-pigmentation agents and to treat and reverse the effects of age and photo damage to the skin. Retinoid compounds are also useful for the prevention and treatment of cancerous and precancerous conditions, including, premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the treatment of Kaposi's sarcoma. In addition, retinoid compounds can be used as agents to treat diseases of the eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well as in the treatment and prevention of various cardiovascular diseases, including, without limitation, diseases associated with lipid metabolism such as dyslipidemias, prevention of post-angioplasty restenosis and as an agent to increase the level of circulating tissue plasminogen activator (TPA). Other uses for retinoid compounds include the prevention and treatment of conditions and diseases associated with human papilloma virus (HPV), including warts and genital warts, various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, improper pituitary function, including insufficient production of growth hormone,

modulation of apoptosis, including both the induction of apoptosis and inhibition of T-Cell activated apoptosis, restoration of hair growth, including combination therapies with the present compounds and other agents such as MinoxidilR, diseases associated with the immune system, including use of the present compounds as immunosuppressants and immunostimulants, modulation of organ transplant rejection and facilitation of wound healing, including modulation of chelosis.

United States Patent Nos. 4,740,519 (Shroot et al.), 4,826,969 (Maignan et awl.), 4,326,055 (Loeliger et al.), 5,130,335 (Chandraratna et al.), 5,037,825 (Klaus et al.), 5,231,113 (Chandraratna et al.), 5,324,840 (Chandraratna), Published European Patent Application Nos. 0 176 034 A (Wuest et al.), 0 350 846 A (Klaus et al.), 0 176 032 A (Frickel et al.), 0 176 033 A (Frickel et al.), 0 253 302 A (Klaus et al.), 0 303 915 A (brace et al.), UK Patent Application GB 2190378 A (Klaus et al.), German Patent Application Nos. DE 3715955 Al (Klaus et al.), DE 3602473 Al (Wuest et al., and the articles J. Amer. Acad. Derm. 15: 756 - 764 (1986) (Sporn et al.), Chem. Pharm. Bull. 33: 404-407 (1985) (Shudo et al.), J. Med Chem. 1988 31, 2182 - 2192 (Kagechika et al.), Chemistry and Biology of Synthetic Retinoids CRC Press Inc. 1990 p 334 - 335, 354 (Dawson et al.), describe or relate to compounds which include a tetrahydronaphthyl moiety and have retinoid-like or related biological activity.

United States Patent Nos. 5,278,318, 5,324,840, 5,324,744, 5,346,895, 5,346,915, 5,348,972, 5,348,975, 5,354,752 assigned to the assignee of the present application, describe or relate to compounds which include a chromanyl, thiochromanyl, or 1,2,3,4-tetrahydroquinolinyl moiety and have retinoid-like or related biological activity.

United States Patent No. 5,344,959 describes cyclopropyl substituted 1,3-butadiene derivatives having retinoid-like biological

activity.

Several co-pending applications and recently issued patents which are assigned to the assignee of the present application, are directed to further compounds having retinoid-like biological activity.

SUMMARY OF THE INVENTION The present invention covers compounds of Formula 1 Formula 1 wherein Z is selected from the radicals shown in Formula 2 or in Formula 3, Formula 2 Formula 3 Y is cycloalkyl or cycloalkenyl of 3 to 8 carbons optionally substituted with one or two R4 groups, or Y is selected from phenyl, pyridyl, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, and imidazolyl, said groups being optionally substituted with one or two R4 groups, the divalent Y radical being substituted by the Z and -CRl=CRl-CRl=CRl groups on adjacent

carbons; X is S, O, or NR5; n is 1 or 2; Rl and R2 independently are H, lower alkyl or fluoroalkyl; R3 is hydrogen, lower alkyl, Cl or Br; R4 is lower alkyl, fluoroalkyl or halogen; Ras is H or lower alkyl, and B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOT8, CONR9Rlo -CH2OH, CH2ORll, CH2OCORll, CHO, CH(OR12)2, CHORl3O, -COR7, CR7(OR12)2, CR7ORl3O, or tri-lower alkylsilyl, where R7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R8 is an alkyl group of 1 to 10 carbons, a cycloalkyl group of 5 to 10 carbons or trimethylsilylalkyl where the alkyl group has 1 to 10 carbons, or R8 is phenyl or lower alkylphenyl, R9 and Rlo independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl or lower alkylphenyl, R11 is lower alkyl, phenyl or lower alkylphenyl, R, is lower alkyl, and Rl3 is divalent alkyl radical of 2-5 carbons.

In a second aspect, this invention relates to the use of the compounds of Formula 1 for the treatment of skin-related diseases, including, without limitation, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hyperproliferative disorders of the skin, eczema, atopic dermatitis, Darriers disease, lichen planus, prevention and reversal of glucocorticoid damage (steroid atrophy), as a topical anti-microbial, as skin anti-pigmentation agents and to treat and reverse the effects of age and photo damage to the skin. The compounds are also useful for the prevention and treatment of cancerous and precancerous conditions, including, premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate,

cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the treatment of Kaposi's sarcoma. In addition, the present compounds can be used as agents to treat diseases of the eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well as in the treatment and prevention of various cardiovascular diseases, including, without limitation, diseases associated with lipid metabolism such as dyslipidemias, prevention of post-angioplasty restenosis and as an agent to increase the level of circulating tissue plasminogen activator (TPA). Other uses for the compounds of the present invention include the prevention and treatment of conditions and diseases associated with Human papilloma virus (HPV), including warts and genital warts, various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, improper pituitary function, including insufficient production of growth hormone, modulation of apoptosis, including both the induction of apoptosis and inhibition of T-Cell activated apoptosis, restoration of hair growth, including combination therapies with the present compounds and other agents such as MinoxidilR, diseases associated with the immune system, including use of the present compounds as immunosuppressants and immunostimulants, modulation of organ transplant rejection and facilitation of wound healing, including modulation of chelosis.

This invention also relates to a pharmaceutical formulation comprising a compound of Formula 1 in admixture with a pharmaceutically acceptable excipient.

In another aspect, this invention relates to processes for making a compound of Formula 1 which processes comprise reacting a compound

of Formula 4 with a compound of Formula 5 in the presence of strong base, or reacting a compound of Formula 4 with a compound of Formula 6 in the presence of strong base. Alternatively, in the processes for making a compound of Formula 1, the aldehyde function of Formula 4 and the dialkylphosphonate of Formula 5, or the triphenylphosphonium bromide function of Formula 6, can be interchanged. In Formula 5 and Formula 6 the symbol B' represents B as defined above in connection with Formula 1, or such protected derivative of the group B from which the B group can be readily obtained by reactions well known to the practicing organic chemist. Still further, the present invention relates to such reactions performed on the compounds of Formula 1 which cause transformations of the B group while the reaction product still remains within the scope of Formula 1.

Formula 4 Formula 5 Formula 6

General Embodiments Definitions The term alkyl refers to and covers any and all groups which are known as normal alkyl, branched-chain alkyl and cycloalkyl. The term alkenyl refers to and covers normal alkenyl, branch chain alkenyl and cycloalkenyl groups having one or more sites of unsaturation. Similarly, the term alkynyl refers to and covers normal alkynyl, and branch chain alkynyl groups having one or more triple bonds.

Lower alkyl means the above-defined broad definition of alkyl groups having 1 to 6 carbons in case of normal lower alkyl, and as applicable 3 to 6 carbons for lower branch chained and cycloalkyl groups. Lower alkenyl is defined similarly having 2 to 6 carbons for normal lower alkenyl groups, and 3 to 6 carbons for branch chained and cyclo- lower alkenyl groups. Lower alkynyl is also defined similarly, having 2 to 6 carbons for normal lower alkynyl groups, and 4 to 6 carbons for branch chained lower alkynyl groups.

The term "ester" as used here refers to and covers any compound falling within the definition of that term as classically used in organic chemistry. It includes organic and inorganic esters. Where B of Formula 1 is -COOH, this term covers the products derived from treatment of this function with alcohols or thioalcohols preferably with aliphatic alcohols having 1-6 carbons. Where the ester is derived from compounds where B is -CH2OH, this term covers compounds derived from organic acids capable of forming esters including phosphorous based and sulfur based acids, or compounds of the formula -CH2OCORll where R11 is any substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aliphatic aromatic group, preferably with 1-6 carbons in the aliphatic portions.

Unless stated otherwise in this application, preferred esters are derived from the saturated aliphatic alcohols or acids of ten or fewer

carbon atoms or the cyclic or saturated aliphatic cyclic alcohols and acids of 5 to 10 carbon atoms. Particularly preferred aliphatic esters are those derived from lower alkyl acids and alcohols. Also preferred are the phenyl or lower alkyl phenyl esters.

Amides has the meaning classically accorded that term in organic chemistry. In this instance it includes the unsubstituted amides and all aliphatic and aromatic mono- and di- substituted amides. Unless stated otherwise in this application, preferred amides are the mono- and di-substituted amides derived from the saturated aliphatic radicals of ten or fewer carbon atoms or the cyclic or saturated aliphatic-cyclic radicals of 5 to 10 carbon atoms. Particularly preferred amides are those derived from substituted and unsubstituted lower alkyl amines. Also preferred are mono- and disubstituted amides derived from the substituted and unsubstituted phenyl or lower alkylphenyl amines.

Unsubstituted amides are also preferred.

Acetals and ketals include the radicals of the formula-CK where K is (-OR)2. Here, R is lower alkyl. Also, K may be -OR7O- where R7 is lower alkyl of 2-5 carbon atoms, straight chain or branched.

A pharmaceutically acceptable salt may be prepared for any compounds in this invention having a functionality capable of forming such-salt, for example an acid functionality. A pharmaceutically acceptable salt is any salt which retains the activity of the parent compound and does not impart any deleterious or untoward effect on the subject to which it is administered and in the context in which it is administered. Pharmaceutically acceptable salts may be derived from organic or inorganic bases. The salt may be a mono or polyvalent ion.

Of particular interest are the inorganic ions, sodium, potassium, calcium, and magnesium. Organic salts may by be made with amines, particularly ammonium salts such as mono-, di- and trialkyl amines or ethanol amines. Salts may also be formed with caffeine, tromethamine

and similar molecules. Where there is a nitrogen sufficiently basic as to be capable of forming acid addition salts, such may be formed with any inorganic or organic acids or alkylating agent such as methyl iodide.

Preferred salts are those formed with inorganic acids such as hydrochloric acid, sulfuric acid or phosphoric acid. Any of a number of simple organic acids such as mono-, di- or tri- acid may also be used.

The compounds of the present invention have trans and cis (E and Z) isomers. In addition, the compounds of the present invention may contain one or more chiral centers and therefore may exist in enantiomeric and diastereomeric forms. The scope of the present invention is intended to cover all such isomers per se, as well as mixtures of cis and trans isomers, mixtures of diastereomers and racemic mixtures of enantiomers (optical isomers) as well. In the present application when no specific mention is made of the configuration (cis, trans or R or S) of a compound (or of an asymmetric carbon) then a mixture of such isomers, or either one of the isomers is intended. In a similar vein, when in the chemical structural formulas of this application a straight line representing a valence bond is drawn to an asymmetric carbon, then isomers of both R and S configuration, as well as their mixtures are intended. A straight horizontal single line or a wavy single line drawn to a carbon with a double bond denotes either cis or trans or both orientations of the substituent on the double bond. Specific orientation of substituents relative to a double bond is indicated in the name of the respective compound, and/or by specifically showing in the structural formula the orientation of the substituents relative to the double bond.

With reference to the symbol Y in Formula 1, the preferred compounds of the invention are those where Y is cyclopropyl, phenyl, pyridyl, thienyl, or furyl. Even more preferred are compounds where Y is cyclopropyl or phenyl. In the preferred compounds of the invention

there is no optional R4 substituent on the Y group.

The Rl substituent of the preferred compounds of the inventiomis preferably H or methyl. The B substituent of the preferred compounds is COOH or a pharmaceutically acceptable salt thereof, or COOT, or CONR9Rlo where R8, R9 and Rlo are as defined above. Even more preferably R8, R9 and Rlo are lower alkyl.

Referring now to the radical symbolized by Z in Formula 1, it is preferably 5,6,7,8-tetrahydronaphthyl (Formula 2 where n is 2), chromanyl or thiochromanyl (Formula 3 where X is S or O). The Y group is preferably attached to the tetrahydronaphthalene group in the 2 or 3 position, and to the chroman or thiochroman ring in the 6 or 7 position. The R3 substituent is preferably H or lower alkyl. Even more preferably the R3 group is H or methyl, the Y group is attached to the tetrahydronaphthalene ring in the 2 position and to the chroman or thiochroman ring in the 6-position. The R2 group is preferably H or methyl.

Specific preferred compounds in accordance with Formula 1 and their synthesis are described below in the section of this application titled "Specific Examples". The presently most preferred compounds of the invention in accordance with Formula 1 are indicated in Table 1 below, with reference to Formula 7, Formula 8 and Formula 9. The numbering of the pentadienoic acid chain of these compounds is indicated in Formula 7. In the preferred compounds of the invention the 4 double bond is trans.

Formula 7 Formula 8

Formula 9 TABLE 1 Compound Formula X R3 R'8 Config- Config- Config- Number uration uration uration about about about cyclo- A2 A4 propane bond bond 1 7 - H Et cis trans trans 2a1 7 - H H cis trans trans 2b2 7 - H H cis trans trans 2 7 - H H cis trans trans 3 7 - H Et trans cis trans 4 7 - H Et trans trans trans 5 7 - H H trans cis trans 6 7 - H H trans trans trans 7 8 - H Et --- trans trans 8 8 - H Et --- cis trans 9 8 - H H --- trans trans 10 8 - H H --- cis trans 11 7 - CH3 Et cis trans trans 12 7 - CH3 Et cis cis trans 13 7 - CH3 H cis trans trans 14 7 - CH3 H cis cis trans

15 9 S H Et cis trans trans 16 9 S H Et cis cis trans 17 9 S H H cis trans trans 18 9 S H H cis cis trans 19 9 0 H Et cis trans trans 20 9 0 H Et cis cis trans 21 9 0 H H cis trans trans 1 optically substantially pure dextro rotatory enantiomer.

2 optically substantially pure levo rotatory enantiomer.

Modes of Administration The compounds of this invention may be administered systemically or topically, depending on such considerations as the condition to be treated, need for site-specific treatment, quantity of drug to be administered, and numerous other considerations.

In the treatment of dermatoses, it will generally be preferred to administer the drug topically, though in certain cases such as treatment of severe cystic acne or psoriasis, oral administration may also be used.

Any common topical formulation such as a solution, suspension, gel, ointment, or salve and the like may be used. Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example, Remington's Pharmaceutical Science, Edition 17, Mack Publishing Company, Easton, Pennsylvania.

For topical application, these compounds could also be administered as a powder or spray, particularly in aerosol form. If the drug is to be administered systemically, it may be confected as a powder, pill, tablet or the like or as a syrup or elixir suitable for oral administration. For intravenous or intraperitoneal administration, the compound will be prepared as a solution or suspension capable of being administered by injection. In certain cases, it may be useful to formulate these compounds by injection. In certain cases, it may be useful to formulate

these compounds in suppository form or as extended release formulation for deposit under the skin or intramuscular injection.

Other medicaments can be added to such topical formulation for such secondary purposes as treating skin dryness; providing protection against light; other medications for treating dermatoses; medicaments for preventing infection, reducing irritation, inflammation and the like.

Treatment of dermatoses or any other indications known or discovered to be susceptible to treatment by retinoic acid-like compounds will be effected by administration of the therapeutically effective dose of one or more compounds of the instant invention. A therapeutic concentration will be that concentration which effects reduction of the particular condition, or retards it expansion. In certain instances, the compound potentially may be used in prophylactic manner to prevent onset of a particular condition.

A useful therapeutic or prophylactic concentration will vary from condition to condition and in certain instances may vary with the severity of the condition being treated and the patient's susceptibility to treatment. Accordingly, no single concentration will be uniformly useful, but will require modification depending on the particularities of the disease being treated. Such concentrations can be arrived at through routine experimentation. However, it is anticipated that in the treatment of, for example, acne, or similar dermatoses, that a formulation containing between 0.01 and 1.0 milligrams per mililiter of formulation will constitute a therapeutically effective concentration for total application. If administered systemically, an amount between 0.01 and 5 mg per kg per day of body weight would be expected to effect a therapeutic result in the treatment of many disease for which these compounds are useful.

Assay of Retinoid-like Biological Activitv The retinoid-like activity of the compounds of the invention can

be confirmed in assays wherein ability of the compound to modulate processes mediated by retinoid receptors, and ability of the compounds to bind to retinoid receptors is measured. It is now general knowledge in the art that two main types of retinoic acid receptors exists in mammals (and other organisms). The two main types or families are respectively designated RAR and RXR receptors. Within each type there are sub-types, designated RARE, RAR , RARE, RXRa, RXR and RXRF. It has also been established in the art that the distribution of the two main retinoid receptor types, and of the several sub-types is not uniform in the various tissues and organs of mammalian organisms.

Moreover, specific or selective agonist-like activity on RXR receptors, in preference over RAR receptors tends to result in certain beneficial retinoid-like properties while avoiding certain undesirable side effects.

Similarly, selective agonist like activity of only one or two retinoid receptor subtypes within one retinoid receptor family can also give rise to beneficial pharmacological properties because of the varying distribution of the sub-types in the several mammalian tissues or organs.

For the above-summarized reasons, agonist-like activity in any or all of the retinoid receptors, as well as specific or selective activity in the RXR receptor family, or selective or specific activity in any one of the receptor subtypes, are all considered desirable pharmacological properties.

In light of the foregoing the prior art has developed assay procedures for testing the agonist like activity of compounds in the RAR,, RAR , RARr, RXRa, RXRB and RXRF receptor subtypes. For example, a chimeric receptor transactivation assay which tests for agonist-like activity in the RAR, RAR , RARE, RXR, receptor subtypes, and which is based on work published by Feigner P. L. and Holm M. (1989) Focus, 11 2 is described in detail in published PCT Application No. WO WO94/17796, published on August 18, 1994. The

latter publication is the PCT counterpart of U. S. application serial no.

08/016,404, filed on February 11, 1993, in which a Notice of Allowance has been issued. PCT publication W094/17796 and the specification of U. S. application serial no. 08/016,404 are hereby expressly incorporated by reference.

A holoreceptor transactivation assay and a ligand binding assay which measure the agonist like activity of the compounds of the invention, or their ability to bind to the several retinoid receptor sub-types, respectively, are described in published PCT Application No.

WO WO93/11755 (particularly on pages 30 - 33 and 37 - 41) published on June 24, 1993, the specification of which is also incorporated herein by reference. A description of the holoreceptor transactivation assay is also provided below.

HOLORECEPTOR TRANSACTIVATION ASSAY CV1 cells (5,000 cells/well) were transfected with an RAR reporter plasmid MTV-TREp-LUC (50 ng) along with one of the RAR expression vectors (10 ng) in an automated 96-well format by the calcium phosphate procedure of Heyman et al. Cell 68, 397 - 406. (8).

For RXR transactivation assays, an RXR-responsive reporter plasmid CRBP II-TK-LUC (50 ng) along with one of the RXR expression vectors (10 ng) was used substantially as described by Heyman et al. above, and Allegretto et al. J. Biol. Chem. 268, 26625 - 26633. (8, 9).

RXR-reporter contained DRI elements from human CRBP II promoter (see Mangelsdorf et al. The Retinoids: Biology, Chemistry and Medicine, pp 319 - 349, Raven Press Ltd., New York and Hevman et al cited above) (1, 8). A 13-galactosidase (50 ng) expression vector was used as an internal control in the transfections to normalize for variations in transfection efficiency. The cells were transfected in triplicate for 6 hours, followed by incubation with retinoids for 36 hours, and the extracts were assayed for luciferase and -galactosidase

activities. The detailed experimental procedure for holoreceptor transactivations has been described in Heyman et al. above, and Allegretto et al. cited above. The results obtained in this assay in connection with examplary compounds in accordance with the present invention are expressed in EC50 numbers, as they are also in the chimeric receptor transactivation assay. The Heyman et al. Cell 68, 397 - 406, Allegretto et al. J. Biol. Chem. 268, 26625 - 26633, and Mangelsdorf et al. The Retinoids: Biology, Chemistry and Medicine, pp 319 - 349, Raven Press Ltd., New York, are expressly incorporated herein by reference. The results of ligand binding assay are expressed in KD5o numbers.

Table 2 below shows the results of the holoreceptor transactivation assay and Table 3 discloses the efficacy (in percentage) in this assay of the compound relative to all trans retinoic acid, for certain exemplary compounds of the invention. Table 4 shows the results of the ligand binding assay for certain exemplary compounds of the invention.

TABLE 2 Holoreceptor Transactivation Assay Compound # EC50 (nanomolar) RARcg RARB RARy RXRcu RXRB RXRy 2 0.0 0.0 170 1.80 1.60 0.79 2a 0.0 0.0 0.0 0.5 0.7 0.6 2b 0.0 0.0 60 27 26 25 6 2100 340 200 2400 2300 2500 9 0.0 0.0 0.0 290 190 240 13 0.0 0.0 0.0 130 100 71.0 17 1200 48 270 30.0 19.0 13.0 21 0.0 1800 0.0 27.0 25.0 29.0 0.0 in Table 2 indicates a value greater than 1000nM

TABLE 3 Transactivation Assay Afficacy (% of RA activity) Compound # RARa RARB RARy RXRa RXRB RXRy 2 10.0 15.0 28.00 76.00 110.0 68.0 2a 1.0 1.0 3.0 126.0 126.0 75 2b 3.0 11.0 19.0 89.0 91.0 78.0 6 29.0 44.0 67.0 33.0 20.0 43.0 9 2.0 8.0 8.0 59.0 94.0 50.0 13 0.0 3.0 8.0 55.0 72.0 40.0 17 30 29 41 111 118 73 21 4.0 26.0 14.0 83.0 93.0 85.0 TABLE 4 Ligand Binding Assay Compound # KDsO(nanomolar) RARa RARI3 RARy RXRa RXRI3 RXRy 2 0.0 0.0 0.0 1.0 1.50 1.30 2a 0.0 0.0 0.0 0.5 3.4 2.5 2b 5750 6202 0.0' 60 210 75 13 0.0 0.0 0.0 71.0 56.0 42.0 17 0.0' 2137 3386 2.5 8.8 7.9 21 0.0 0.0 0.0 5.0 6.0 12.00 0.0 in Table 4 indicates a value greater than 1000nM 1 indicates a value greater than 10,000 As it can be seen from the foregoing Tables 2-4, Compound 2a, which is the optically pure dextro rotatory enantiomer (+) 3,7-dimethyl- <BR> <BR> <BR> 6(S),7(S)-methano-7(5,5,8,8-tetramethyl-5,6,7,8-tetrahydrona phth-2-yl)-

2(E),4(E)-heptadienoic acid has very strong RXR specific binding affinity, and RXR specific agonist-like activity.

It is also apparent from Tables 2-4 that the levo rotatory enantiomer Compound 2b while still selective, is not quite as specific to RXR receptors in preference over RAR receptors as the dextro rotatory enantiomer Compound 2a. Compound 2a is also significantly more active than Compound 2b.

SPECIFIC EMBODIMENTS Synthetic Processes for Preparing Compounds of the Invention The compounds of this invention can be made by a number of different synthetic chemical pathways. To illustrate this invention, there is here outlined a series of steps which have been proven to provide the compounds of Formula 1 when such synthesis is followed in fact and in spirit. The synthetic chemist will readily appreciate that the conditions set out here are specific embodiments which can be generalized to any and all of the compounds represented by Formula 1. Furthermore, the synthetic chemist will readily appreciate that the herein described synthetic steps may be varied and or adjusted by those skilled in the art without departing from the scope and spirit of the invention.

DMSO, ,,YO Z'Y'ctnoH 2 (CF,CO)O,E4N F Po=ulalO Edition Form u YO + Frr EtO%?lPIB. > «çfs' IC1 Pormida U FODE 12 Formula 13 3 Hoaolop and dezivatiwe Reaction Scheme 1

Referring now to Reaction Scheme 1 a primary or secondary alcohol of Formula 10 is the starting material. The symbols Z, Y and Rl in this reaction scheme are defined as in connection with Formula 1. In the presently preferred embodiments the Rl group of Formula 10 is hydrogen, and therefore the starting material is a primary alcohol.

Examples of the primary alcohols which are used for the preparation of the preferred compounds of the present invention are <BR> <BR> <BR> <BR> 3-methyl-2(RS),3(SR)-methano-3[5,5,8,8-tetramethyl-5,6,7,8-t etrahydron <BR> <BR> <BR> <BR> <BR> <BR> <BR> aphth-2-yl]propan- 1-ol, 3-methyl-2(RS),3(RS)-methano-3{5,5,8,8- <BR> <BR> <BR> <BR> <BR> <BR> tetramethyl-5,6,7,8-tetrahydronaphth-2-yl]propan- 1 -ol, <BR> <BR> <BR> <BR> <BR> <BR> <BR> 2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)benzyla lcohol, <BR> <BR> <BR> <BR> <BR> <BR> <BR> 3-methyl-2(RS) ,3 (SR)-methano-3 [4,4-dimethyl-thiochroman-6-yl]propan- 1-ol, 3-methyl-2(RS),3(SR)-methano-3[4,4-dimethyl-chroman -6-yl]propan-1-ol, 2-(4,4-dimethyl-thiochroman-6-yl)benzyl alcohol, 2-(4,4-dimethyl-chroman-6-yl)benzyl alcohol, 3-methyl-2(RS),3(SR)- methano-3 [4,4-dimethyl- 1 ,2,3,4-tetrahydroquinolin-6-yl]propan- 1 -ol and 2-(4,4-dimethyl- 1,2,3,4-tetrahydroquinolin-6-yl)benzyl alcohol. Examples of the starting alcohol of Formula 10 for the preparations of compounds of the invention where Y is cyclopentyl or cyclohexyl are [2-(5,5,8,8- tetramethyl-5 ,6,7,8-tetrahydronaphth-2-yl)-cyclopentyl] -methanol, [2-(5 ,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)-cyclohexyl l -methan ol, [2-(4,4-dimethyl-thiochroman-6-yl)cyclopentyl] -methanol, 2- (4,4-dimethyl-thiochroman-6-yl)cyclohexyl]-methanol, 2-(4,4-dimethyl-chroman-6-yl)cyclopentyl] -methanol, <BR> <BR> <BR> <BR> 2-(4,4-dimethyl-chroman-6-yl)cyclohexyl]-methanol, <BR> <BR> <BR> <BR> <BR> <BR> <BR> [2-(4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)cyclopentyl ]-methanol, <BR> <BR> <BR> <BR> <BR> <BR> <BR> 2- (4,4-dimethyl- 1 ,2,3,4-tetrahydroquinolin-6-yl) cyclohexyl] -methanol.

The alcohol of Formula 10 is oxidized to provide the oxo compound of Formula 11. The oxidation can be carried out with a number of oxidizing agents known in the art; one suitable condition

employed for the synthesis of the presently preferred embodiments is stirring the alcohol of Formula 10 with dimethylsulfoxide and trifluoroacetic anhydride, or with dimethylsulfoxide and oxalyl chloride, followed by tretment with triethylamine. The oxo compound (aldehyde when Rl is H) of Formula 11 is not necessarily isolated in an absolutely pure form, and can be used in a crude form in the next coupling reaction with the diethylphosphono reagent of Formula 12. The symbol Rl in Formula 12 is defined as in connection with Formula 1; in the preferred embodiments Rl of Formula 12 is H or methyl. The B' group of Formula 12 is defined as the B group of Formula 1, or such a protected derivative or precursor of B which can undergo and withstand the conditions of the Horner Emmons coupling reaction and from which the desired B group can be obtained by reactions well known to the practicing organic chemist. Typically, and preferably the B' group is an esterified carboxylic acid; an example of the reagent used for the preparation of the preferred compounds of the invention is ethyl dieth- ylphosphono-3-methyl-2(E)-butenoate which can be obtained in accordance with the chemical literature (J. Org. Chem. 1974 Volume 39 p. 821). As is known in the art, the Horner Emmons reaction is conducted in the presence of strong base (such as butyl lithium) in an inert solvent (such as tetrahydrofuran) and results in the formation of a double bond to replace the oxo function of the reagent of Formula 11.

The resulting product is a diene of Formula 13, wherein the B' group represents the B group of Formula 1 or a protected derivative thereof.

In the preferred embodiments the B' or B group is a carboxylic acid or its ester, and therefore the presently preferred compounds of the invention are derivatives of 2,4-pentadienoic acid. Instead of the Horner Emmons reagent of Formula 12, an analogous Wittig reagent can also be utilized in the coupling reaction. The structure of such a Wittig reagent will be readily apparent to those skilled in the art in light

of the present disclosure. The herein described Horner Emmons coupling reaction typically provides as predominant product the isomer where the configuration about the newly formed double bond ( 4 of the pentadienoic acid) is trans, and normally only this trans isomer is isolated from the reaction mixture. However, it is also possible to obtain a greater proportion of the corresponding cis isomer by adjusting conditions of the Horner Emmons reaction. As noted above, the B' group of the compounds of Formula 13 can be subjected to such reactions which are well within the skill of the practicing organic chemist, and which either result in the deprotection of B' to yield a B group within the scope of the invention, or which convert the B group into other functions still within the scope of the invention. Examples of the latter reactions are saponification, esterification, transesterification, amide formation, reduction to aldehyde and homologation. These reactions are indicated in Reaction Scheme 1 by conversion to "homologs and derivatives".

+ 'rCPzt : COVET o Z F«nula 14 F«nuls 15 Formula 16 Rl=H 0 BrrsCO2Et RI Formula U FonnPlr RI =loweraikyi zna2, NI(PIPCI? DiBAI-H Z CO2Et Z CO2Et > Z' CH20H Poms ld Pormrrt 19 Pdal9 h10 Reaction Scheme 2

Referring now to Reaction Scheme 2, a general synthetic route is disclosed for obtaining the starting material used in the synthetic route described in Reaction Scheme 1 for the situation where in the formula of the compounds of the invention Y represents an aryl or heteroaryl group. Such group is symbolized by Y' in the reaction scheme. In accordance with this scheme, a Grignard or like organometallic reagent of Formula 14 is prepared from a compound of the formula Z-Br, and the Grignard reagent is reacted with bromo (or other halogeno) compound of Formula 15 in the presence of zinc chloride and triphenylphosphine nickel dichloride to obtain a carboxylate ester of Formula 16. The Z group is defined as above in connection with Formula 1.

An example of the reagent Z-Br utilized for the synthesis of certain preferred compounds of the invention is 2-bromo-5 ,5,8,8-tetramethyl-5 ,6,7,8-tetrahydronaphthalene (available in accordance with the chemical literature, see Journal of Medicinal Chemistry 1983 Vol. 26 p. 1653). Another example is 6- or 7-bromo-4,4-dimethylchroman, and 6- or 7-bromo-4,4-dimethylthiochroman which are available in accordance with the teachings of United States Patent Nos. 5,348,972 and 5,053,523 the specifications of which is incorporated herein by reference.

In order for the modified Grignard coupling reaction between the reagents of Formula 14 and Formula 15 to proceed well, the bromo atom of the compound of Formula 15 must be attached to an aromatic (or heteroaromatic) carbon, or to a vinylic carbon. For this reason, the reagent of Formula 15 is a brominated (or other halogenated) aryl-carboxylic acid ester, or bromo-heteroaryl carboxylic acid ester.

These reagents are either commercially available, or generally speaking, can be prepared in accordance with the state of the art. An example for the reagent of Formula 15 which is used for the synthesis of certain

preferred compounds of the invention is ethyl 2-bromobenzoate. Other examples for the reagent of Formula 15 are: ethyl 2-bromo-pyridine-3-carboxylate, ethyl 2-bromothiophene-3-carboxylate and ethyl 2-bromofuran-3-carboxylate.

The carboxylate ester product of Formula 16 is reduced with a suitable reducing agent, such as diisobutyl aluminum hydride (dibAlH) in an inert solvent such as methylene chloride, to yield the primary alcohol of Formula 10 where Rl is hydrogen. The primary alcohol of Formula 10 is the starting material indicated in Reaction Scheme 1.

The carboxylate ester compound of Formula 16 can also be converted to a ketone by a Grignard or modified Grignard reaction to yield the compounds of Formula 11 where the Rl group is lower alkyl. The ketone compounds of Formula 11 can also serve in accordance with Reaction Scheme 1 for the synthesis of the compounds of the invention.

The synthetic methodology described above in connection with Reaction Scheme 2 is also suitable for preparation of compounds of the invention where the Y group is cycloalkyl, other than cyclopropyl. In such case, a brominated cycloalkenyl carboxylate ester of Formula 17 is reacted with the Grignard (or like organometallic) reagent of Formula 14 in the presence of zinc chloride and bis triphenyl phosphine nickel (II) chloride to provide compounds of Formula 18. Examples of reagents of Formula 17 are ethyl 2-bromocyclohexene carboxylate and ethyl 2-bromocyclopentene carboxylate. Accordingly, the Y,' in Formula 17 represents a cycloalkene ring. Compounds of Formula 18 are subjected to hydrogenation to saturate the double bond in the cycloalkene ring, and thereafter reduced with diisobutyl aluminum hydride (dibAlH) to yield the primary alcohols of Formula 10. Y," of Formula 19 of Reaction Scheme 2 represents a cycloalkyl ring.

Compounds of Formula 17 can also be reduced to the alcohols of Formula 10 and follow Reaction Scheme 1 to provide cycloalkenyl

compounds of the<BR> compounds of the invention, as defined in Formula 1 where Y is cycloalkenyl. Ml = ç zz FonaPk ld Farmrrlr 21 )¼cuu ZvvtFOH CH21a Z=g=OH Di H Z*= J IIgC Sm Formula 10 FonnrJ1 23 Ponnula22 b q COOH Formula 24 Et <20H Formula 10 Reaction Scheme 3

Reaction Scheme 3 discloses a synthetic route for the preparation of the starting primary alcohol (in accordance with Formula 10) for the synthesis of the preferred compounds of the invention where the Y group of Formula 1 is methylcyclopropyl. In accordance with this reaction scheme, an ethyne compound of the formula Z-C--CH (Formula 20) is reacted with ethyl chloroformate (or methylchloroformate) in the presence of strong base (butyl lithium) in an inert solvent (such as hexane) to yield the propiolate compound of Formula 21. The ethyne compounds of Formula 20 are, generally speaking, known in the art. An examplary compound of Formula 20 which is used for the synthesis of the herein described preferred embodiments is 2-ethynyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene which can be obtained in accordance with the chemical literature, see The Retinoid: Biology, Chemistry and Medicine 2nd Edition, Editors Sporn et al., Raven Press Ltd. N.Y. 1994, Chapter 2, pg 157. Further examples are (4,4-dimethyl-thiochroman-6-yl)ethyne, (4,4-dimethyl-chroman-6-yl)ethyne, (4,4-dimethyl- 1,2,3,4-tetrahydroquinolin-6-yl)ethyne, (2,2,4,4-tetramethyl-thiochroman-6-yl) ethyne, (2,2,4,4-tetramethyl-chroman- 6-yl)ethyne, (2,2,4,4-tetramethyl- 1 ,2,3,4-tetrahydroquinolin-6-yl)ethyne, which can be obtained in accordance with the teachings of United States Patent Nos.

5,053,523, 5,278,318, 5,346,895 and 5,348,972, the specifications of which is incorporated herein by reference. The propiolate compound of Formula 21 is thereafter reacted with methyl lithium in the presence of copper(I)bromide-dimethylsulfide in an inert solvent such as tetrahydrofuran. The reaction results in addition of the methyl group to the double bond, to yield the enoate compound of Formula 22.

Depending on the reaction conditions which are described in detail

below in the description of the specific embodiments, compounds of Formula 22 of both cis and trans orientation about the double bond can be obtained in this manner. The enoate compound of Formula 22 is thereafter reduced with a suitable reagent, such as diisobutyl aluminum hydride, to yield the primary alcohol of Formula 23. In the next step, the double bond of the alcohol of Formula 23 is converted into a cyclopropyl ring in a cyclopropylation reaction which employs the reagent diiodomethane in the presence mercury(II)chloride, and samarium. The cyclopropylation reaction is usually conducted at cold temperature (-78 oC), in an inert solvent such as tetrahydrofuran in an inert (argon) gas atmosphere. In the cyclopropylation reaction the orientation (cis or trans) of the double bond to which the methylene group is attached, is maintained. However, cyclopropylation in the presence of mercury (II) chloride catalyst provides no enantio selectivity. As is described in more detail below, enantio selectivity can be achieved by using optically active diethyl tartrate as a catalyst. In either case, from a cis allylic alcohol of Formula 23 a cis cyclopropyl derivative is obtained, whereas a trans allylic alcohol of Formula 23 yields a trans cyclopropyl derivative. The product of the cyclopropylation reaction is the alcohol of Formula 10 (where Y is methylcyclopropyl) which is used as the starting compound for the synthesis of the compounds of the invention in accordance with Reaction Scheme 1. The unsaturated alcohol of Formula 23 (or preferably an ester thereof) can also be reacted with a diene compound (such as 1,3-butadiene) under Diels Alder conditions (heating in a sealed tube) to yield a cyclohexene derivative of Formula 24, which, after saturation of the double bond by hydrogenation, yields the alcohol of Formula 10, where Y is methyl cyclohexyl.

Referring now back to Reaction Scheme 1 and to the preparation of homologs and derivatives of the compounds of the invention, as well

as to transformations of the B' group which may become necessary to obtain a desired reagent in accordance with Formula 12, where such reagent is not available commercially or from a known literature procedure, the following synthetic methodology is noted.

Carboxylic acids are typically esterified by refluxing the acid in a solution of the appropriate alcohol in the presence of an acid catalyst such as hydrogen chloride or thionyl chloride. Alternatively, the carboxylic acid can be condensed with the appropriate alcohol in the presence of dicyclohexylcarbodiimide and dimethylaminopyridine. The ester is recovered and purified by conventional means. Acetals and ketals are readily made by the method described in March, "Advanced Organic Chemistry," 2nd Edition, McGraw-Hill Book Company, p 810).

Alcohols, aldehydes and ketones all may be protected by forming respectively, ethers and esters, acetals or ketals by known methods such as those described in McOmie, Plenum Publishing Press, 1973 and Protecting Groups, Ed. Greene, John Wiley & Sons, 1981.

The acids and salts derived from compounds of Formula 1 are readily obtainable from the corresponding esters. Basic saponification with an alkali metal base will provide the acid. For example, an ester of Formula 1 may be dissolved in a polar solvent such as an alkanol, preferably under an inert atmosphere at room temperature, with about a three molar excess of base, for example, lithium hydroxide or potassium hydroxide. The solution is stirred for an extended period of time, between 15 and 20 hours, cooled, acidified and the hydrolysate recovered by conventional means.

The amide may be formed by any appropriate amidation means known in the art from the corresponding esters or carboxylic acids. One way to prepare such compounds is to convert an acid to an acid chloride and then treat that compound with ammonium hydroxide or an appropriate amine. For example, the acid is treated with a 10-fold

excess of oxalyl chloride. This is effected at a moderately reduced temperature between about -10 degrees and +10 degrees C. The last mentioned solution is then stirred at the reduced temperature for 1-4 hours, preferably 2 hours. Solvent removal provides a residue which is taken up in an inert organic solvent such as benzene, cooled to about 0 degrees C and treated with concentrated ammonium hydroxide. The resulting mixture is stirred at a reduced temperature for 1 - 4 hours.

The product is recovered by conventional means.

Alcohols are made by converting the corresponding acids to the acid chloride with thionyl chloride or other means (J. March, "Advanced Organic Chemistry", 2nd Edition, McGraw-Hill Book Company), then reducing the acid chloride with sodium borohydride (March, Ibid, pg.

1124), which gives the corresponding alcohols. Alternatively, esters may be reduced with lithium aluminum hydride at reduced temperatures.

Alkylating these alcohols with appropriate alky halides under Williamson reaction conditions (March, Ibid, pg. 357) gives the corresponding ethers. These alcohols can be converted to esters by reacting them with appropriate acids in the presence of acid catalysts or dicyclohexylcarbodiimide and dimethylaminopyridine.

Aldehydes can be prepared from the corresponding primary alcohols using mild oxidizing agents such as pyridinium dichromate in methylene chloride (Corey, E. J., Schmidt, G., Tet. Lett., 399, 1979), or dimethyl sulfoxide/oxalyl chloride in methylene chloride (Omura, K., Swern, D., Tetrahedron 1978, 34, 1651).

Ketones can be prepared from an appropriate aldehyde by treating the aldehyde with an alkyl Grignard reagent or similar reagent followed by oxidation.

Acetals or ketals can be prepared from the corresponding aldehyde or ketone by the method described in March, Ibid, p 810.

H (+) Li tattle Compound 1 CompcwdA2 (rniflof, 1. (-) i<S Cflofl DMAP æ Separion ot Ihe o ,diaXreomers N H CompourdA3 Compo Cornpo A4 (u?1D 10.70 faf10 4O UOH UOH t DIJ H DMS '4 DMso 0 p. Compouw calipu Compoud A1 Opficalvpe CornpoudA;l Corpouwl AS OptIcaI pt,e (dextro Al rotaaory, mir6r) M r,BS SPo (dero rOt1bry minor) ' 114L Cornpoud A Compomd 2 c::i cOmpo Compotaid 2a (deÇtro t Reaction Scheme 4

Reaction Scheme 4 discloses a process for preparing an especially preferred compound of the present invention, namely optically pure (or substantially pure) dextro rotatory (+) 3,7-dimethyl-6(S),7(S)-methano- 7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)-2(E),4 (E)- heptadienoic acid (Compound 2a) and as a side product its levo rotatory enantiomer (-) 3,7-dimethyl-6(R),7(R)-methano-7-(5,5,8,8-tetramethyl- 5 ,6,7,8-tetrahydronaphth-2-yl) -2(E),4(E)-heptadienoic acid (Compound 2b). The first compound shown in Reaction Scheme 4 is 3-(5,5,8,8- tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)but-2-(Z)-en-1-ol (Compound C), which is obtained in accordance with Reaction Scheme 3.

Compound C has the cis (Z) configuration about the double bond. In the first reaction shown in this scheme, Compound C is reacted with diidomethane in the presence of diethyl zinc and (+) L diethyl tartrate to add a methylene group to the double bond and provide a mixture of (-) 3-methyl-2(R),3(S)-methano-3-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydronaphth-2-yl-)propan-1-ol (Compound Al) and of (+) 3- methyl-2(S),3(R)-methano-3-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydronaphth-2-yl-)propan-1-ol (Compound A2). The cis (Z) configuration of the double bond of Compound C is retained in the cyclopropyl ring that is present in Compounds Al and A2. Compounds Al and A2, however are not present in equal amounts in the reaction mixture, because the presence of the (+) L diethyl tartrate catalyst renders the reaction enantio selective, favoring the levo rotatory Compound Al to the dextro rotatory Compound A2 in a ratio of approximately 10 to 1. Compounds Al and A2 can also be made under conditions which are different then the ones summarized above and are described in detail in the experimental section under the heading "Specific Embodiments". The principal difference is that in the latter reaction instead of (+) L diethyl tartrate, mercury(II) chloride is used as a catalyst and a racemic (50 : 50) mixture of Compounds Al and A2

is obtained. The racemic mixture obtained in the reaction that employs the mercury(II) chloride catalyst is designated as "Compound D" in the experimental section.

Returning now to the description of Reaction Scheme 4, the mixture of enatiomeric Compounds Al and A2 is resolved by reacting the mixture with optically pure (-) 1-(S)-camphanic chloride in the presence of N,N-dimethylaminopyridine. This reaction provides a mixture of diastereomeric camphanoic ester derivatives, Compounds A3 and A4. These diastereomeric ester compounds (A3 and A4) are first purified by chromatography on silicagel, and the major diastereomer (Compound A3) is obtained by crystallization from hexane. The absolute sterochemistry of the major diastereomer (Compound A3) was determined by single crystal X-ray crystallography. The pure, or substantially pure diastereomeric ester compounds are saponified by treatment with LiOH in a mixture of methanol and tetrahydrofuran (THF), to give the optically pure alcohols Al (major enantiomer, levo rotatory) and A2 (minor enantiomer, dextro rotatory).

Both pure, or substantially pure, enantiomers Al and A2 are then subjected to a sequence of reactions to convert them into optically pure (or substantially pure) heptadienoic acid derivatives, Compounds 2a and 2b. However, the reaction sequence is explicitly shown in Reaction Scheme 4 only as conducted with the major enantiomeric alcohol (Compound Al), giving rise to Compound 2a. Thus, Compound Al is oxidized in the presence of oxalyl chloride and dimethylsulfoxide (DMSO) to provide the aldehyde, 3-methyl-2(R),3(S)-methano-3- (5,5 ,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl-)propanal (Compound A5). The aldehyde A5 is not stable for prolonged period of time.

After rudimentary purification on a silica gel column Compound A5 is reacted in a Homer Emmons reaction with ethyl-diethylphosphono-3- methyl-2(E)-butenoate to provide (+) ethyl 3,7-dimethyl-6(S),7(S)-

methano-7(5,5,8,8-tetramethyl-5,6,7, 8-tetrahydronaphth-2-yl) -2(E),4(E)- heptadienoate (Compound A6). Compound A6 is saponified with lithium hydroxide ( LiOH) in THF and methanol to give optically pure (+) 3,7-dimethyl-6(S),7(S)-methano-7-(5,5,8,8-tetramethyl-5,6,7, 8- tetrahydronaphth-2-yl) -2(E) ,4(E)-heptadienoic acid (Compound 2a). As it is described above, Compound 2a is significantly active as an RXR receptor specific agonist.

A similar sequence of reactions, starting with 3-methyl-2(S),3(R)- <BR> <BR> <BR> <BR> methano-3-(5 ,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl-)propan- 1 - ol (Compound A2, minor enantiomeric alcohol) leading through the aldehyde, 3-methyl-2(S),3(R)-methano-3-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydronaphth-2-yl-)propanal (Compound A7) followed by the ester, (-) ethyl 3,7-dimethyl-6(R),7(R)-methano-7(5,5,8,8-tetramethyl-5,6,7,8 - tetrahydronaphth-2-yl)-2(E) ,4(E)-heptadienoate (Compound A8) yields optically pure (or substantially pure) (-) 3,7-dimethyl-6(R),7(R)- <BR> <BR> <BR> <BR> methano-7- (5 ,5,8,8-tetramethyl-5 ,6,7,8-tetrahydronaphth-2-yl)-2(E) ,4(E) - heptadienoic acid (Compound 2b). As it is noted above, while still active, the levo rotatory heptadienoic acid derivative Compound 2b is substantially less active as an RXR specific agonist than its dextro rotatory enantiomer.

SPECIFIC EMBODIMENTS Ethyl 3-(5.58.8.-tetramethvl-5,6,7.8-tetrahYdronaphth-2-Yl?propiol ate (Compound A) To a cold solution (-780C) of 2-ethynyl,5,5,8,8-tetramethyl- 5,6,7,8-tetrahydronaphthalene (900mgs, 4. 3mmols) in ether (20ml) was added n-butyllithium in hexane (5.6mmols). The mixture was stirred for 45 mins, and ethylchloroformate (1.3g, 12mmols) was added via syringe.

Stirring was continued for 45 mins then the mixture was warmed gradually to -100C and quenched by adding sodium bicarbonate (NaHCO3) solution (10ml). Diethyl ether (100ml) was added, the

organic phase washed with water (10ml), brine (10ml), and dried (MgS04). The solvent was removed in vacuo. Purification of the residue over silicagel (5% ethylacetate in hexane) gave the title compound as a colorless oil.

PMR (CDCl3) : 3 1.27 (12H, s), 1.36 (3H, t, j=7.5Hz), 1.68 (4H, s), 4.29 (2H, q, j=7.5Hz), 7.30 (1H, d, j=8.2Hz), 7.35 (1H, dd, j=1.6, 8.2Hz), 7.56 (1H, d, j=1.6Hz).

Ethvl 3-(55.88-tetramethvl-5.6*7*8-tetrahydronaphth-2-Yl?but-2(Z)- enoate (Compound B) To a cold (-20°C) solution of copper(I)bromide-dimethylsulfide (CuBr.DMS) (832mgs, 4.06mmols) in THF (30ml) methyllithium in ether (7.95mmols) was added dropwise. The clear solution was stirred for 10 mins, then cooled to -78°C. To this solution ethyl 3- (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphth- 2-yl)propiolate (Compound A, 900mgs, 2.9mmols) in THF (Sml) was added dropwise (10mins). The mixture was stirred for additional 2 hours at -78°C. The reaction was quenched by slow addition of ethanol to the cold (-78°C) solution, followed by water (10ml), and the mixture was diluted with more water (100ml). The organic phase was washed with 10% HCl (10ml), brine (lOml) and dried (MgS04). The solvent was removed in vacuo to give the title compound as a colorless oil.

PMR (CDCl3) : 3 1.03 (3H, t, j=7.5Hz), 1.26 (6H, s), 1.28 (6H, s), 1.68 (4H, s), 2.17 (3H, d, j=1.4Hz), 3.98 (2H, q, j=7.5Hz), 5.86 (1H, q, j=1.4Hz), 6.96 (1H, dd, j=2.0, 8.1Hz), 7.14 (1H, d, j=2.0Hz), 7.26 (1H, d, j=8.1Hz).

3-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphth-2-yl]but- 2(Z)- en- 1-ol (Compound C) To a cold (-78°C) solution of ethyl 3-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydronaphth-2-yl)but-2(Z)-enoate (Compound B 500mgs, 1.66mmols) in THF (20ml) was added DibAl-H in methylene chloride

(6mmols) dropwise (5 mins). The mixture was gradually (4 hours) allowed to warm to -10°C. The reaction was quenched by adding methanol(2ml) followed by 10% HCl, and the mixture was stirred for 5 mins, then diethyl ether (100ml) was added. The organic phase was washed with water (lOml), 10% NaHCO3 (10ml) and brine (10ml) and dried (MgSO4). The solvent was removed in vacuo to afford the title compound as a colorless oil.

PMR (CDCl3): 8 1.28 (6H, s), 1.29 (6H, s), 1.69 (4H, s), 2.10 (3H, brs), 4.13 (2H, d, j=6.9Hz), 5.69 (1H, t, j=6.9Hz), 6.96 (1H, dd, j=2.1, 8.2Hz), 7.09 (1H, d, j=2.1Hz), 7.26 (1H, d, j=8.2Hz). <BR> <BR> <BR> <BR> <P>3-Methvl-2(RS),3(SR?-methano-3(5 58*8-tetramethYl-5678-tetrahYdron aphth-2-vl)propan-1-ol (Compound D) To a flame dried round bottom flask containing samarium (1.125g, 7.5mmols) under argon atmosphere was added THF (10ml), mercury(II)chloride (203mgs, 0.75mmol) in THF (10ml) and 3-(5 ,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)but-2(Z)-en - 1-ol (Compound C 390mgs, 1.5mmols) in THF (5ml), sequentially. The mixture was cooled to -78°C and diiodomethane (2.01g, 7.5mmols) was added via syringe. The mixture was stirred and gradually warmed to ambient temperature (4h). The reaction was quenched by adding potassium carbonate solution (15ml) and extracted with diethyl ether (5X25ml). The organic phase was washed with water (10ml), brine (10ml) and dried (MgSO4). The solvent was removed in vacuo, and purification of the residue by silicagel chromatography (5% ethylacetate in hexane) gave the title compound as a colorless oil.

PMR (CDC13): 8 0.72-0.79 (1H, m), 0.83-0.91 (1H, m), 1.22 - 1.23 (1H, m) 1.26 (6H, s), 1.27 (6H, s), 1.40 (3H, s), 1.67 (4H, s), 3.12-3.22 (1H, m), 3.26-3.34 (1H, m), 7.06 (1H, dd, j=1.9, 8.1Hz), 7.21 (1H, d, 8.1Hz), 7.23 (1H, brs).

Ethyl 37-dimethyl6(RS) 7(SR) methano-7-(55 5,8,8-tetramethyl-5,6,7,8-

tetrahydronaphth-2-yl) 2(E) 4 (E)-heptadienoate (Compound 1) To a cold (-70"C) solution of dimethylsulfoxide (DMSO) (1.09g, 14mmols) in methylene chloride (10ml) was added a solution of trifluoroacetic anhydride (2.52g, 12mmols) in methylene chloride (3ml) dropwise (3 mins). To the stirred (10 mins) mixture was added a solution of 3-methyl-2(RS),3(SR)-methano-3(5,5,8, 8-tetramethyl- 5,6,7,8-tetrahydronaphth-2-yl)propan- 1-ol (Compound D, 598mgs, 2.2mmols) in methylene chloride (3ml) dropwise. The mixture was stirred for additional 30 mins, then triethylamine (3.5g, 35mmols) in methylene chloride (5ml) was added to it. The reaction mixture was allowed to warm to 0°C (over 20 mins) and diluted with methylene chloride (60ml). The organic phase was washed with water (lOml), sodium bicarbonate (10ml) and dried (MgSO4). The solvent was removed in vacuo. Silicagel chromatography (5% ethyl acetate in hexane) of the crude product gave 3-methyl-2(RS),3(SR)-methano- 3(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)propiona ldehyde.

This unstable product was dissolved in dry THF (5ml) and was added to a cold (-78°C) solution of ethyl diethylphosphono-3-methyl-2(E)- butenoate (792mgs, 3mmols) and n-butyllithium (2.88mmols) in THF (10ml). The mixture was stirred for 10 mins and quenched by adding water (10ml) and diluted with diethyl ether (60ml). The organic layer was washed with brine (lOml) and dried (MgSO4). The solvent was removed under reduced pressure. The crude product was purified by silicagel chromatography (3% ethylacetate in hexane) followed by HPLC (2% ethylacetate in hexane) to give the title compound as a colorless oil.

PMR (CDCl3) : 8 1.11-1.20 (2H, m),1.21 (3H, s), 1.28 (9H, s), 1.28 (3H, t, j=7.2Hz), 1.43 (311, s), 1.68 (4H, s), 1.68-1.80 (1H, m), 1.99 (3H, s), 4.15 (2H, q, j=7.2Hz), 5.22 (1H, dd, j=9.9, 15.4Hz), 5.63 (1H, s), 6.20 (1H, d, j=15.4Hz), 7.03 (1H, dd, j=1.9, 8.1Hz), 7.14 (1H, d, j=1.9Hz),

7.23 (1H, d, j=8.1Hz).

3,7-Dimethyl,6(RS),7(SR) methano-7-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydronaphth-2-yl),2(E),4(E)-heptadienoic acid (Compound 2) To a solution of ethyl 3,7-dimethyl,6(RS),7(SR) <BR> <BR> <BR> <BR> methano-7-(5,6,7,8-tetrahydro-5 ,5 ,8,8-tetramethyl-naphth-2-yl) ,2(E) ,4(E)- heptadienoate (Compound 1 104mgs, 027mmols), in THF (2ml) and methanol (lml) was added lithium hydroxide (lmmol) in water, and the mixture was stirred at ambient temperature for 24 hours. Thereafter diethyl ether (60ml) was added, the mixture was acidified with 10% HCl, and the organic phase was washed with water (5ml), brine (5ml), dried (MgSO4) and the solvent was removed in vacuo. Chromatography on silicagel (25% ethylacetate in hexane) gave the title compound as a white solid.

PMR (CDCl3) : # 1.12-1.22 (2H, m), 1.20 (3H, s), 1.27 (9H, s), 1.43 (3H, s), 1.67 (4H, s), 1.68-1.77 (1H, m), 1.98 (3H, s), 5.27 (1H, dd, j=9.9, 15.5Hz), 5.65 (1H, s), 6.21 (1H, d, j=15.5Hz), 7.03 (1H, dd, j=1.8, 8.0Hz), 7.13 (1H, d, j=1.8Hz), 7.23 (1H, d, j=8.0Hz).

Ethyl 3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)but-2(E )-enoate (Compound E) Employing the same general procedure as for the preparation of ethyl 3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)but-2(Z )- enoate (Compound B), but instead using 900gs (2.9mmols) of ethyl 3-(5 ,5 ,8,8,-tetramethyl-5 ,6,7,8-tetrahydronaphth-2-yl)propiolate (Compound A), 832mgs (4.06mmols) of CuBr(I).DMS, 5.6mmols of methyllithium in ether and maintaining the temperature at 0°C the title compound was obtained as a colorless oil.

PMR (CDCl3) : 8 1.29 (6H, s), 1.31(611, s), 1.33 (3H, t, j=7.1Hz), 2.57 (3H, d, j=1.SHz), 4.22 (2H, q, j=7.1Hz), 6.11(1H, d, j=1.SHz), 7.25 (1H, dd, j=1.8, 8.3Hz), 7.31 (1H, d, j=8.3Hz), 7.41(1H, d, j=1.8Hz).

3-(5 588-Tetramethvl-5,6,78-tetrahydronaphth-2-vl? but-2(Z?-en-1-ol (Compound F) Employing the same general procedure as used for the preparation of 3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)but- 2(Z)-en-1-ol (Compound C), but instead using 500mgs (1.66mmols) of ethyl 3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)- but-2(E)-enoate (Compound E) and 6 mmols of diisobutylaluminiumhydride the title compound was obtained as a colorless oil.

PMR (CDCl3): 8 1.29 (6H, s), 1.30 (6H, s), 1.69 (4H, s), 2.08 (3H, s), 4.37 (12H, t, j=6.5Hz), 5.90-5.99 (1H, m), 7.18 (1H, dd, j=1.8, 8.2Hz), 7.27 (1H, d, j=8.2Hz), 7.35 (1H, d, j=1.8Hz).

( +/-)3-Methyl-2(RS),3(RS)-methano-3(5,5,8,8- tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)propan-1-ol (Compound G) Employing the same general procedure as used for the preparation of 3-methyl-2(RS),3(SR)-methano-3(5,6,7,8-tetrahydro- 5,5,8,8-tetramethyl-naphth-2-yl)propan-1-ol (Compound D), but instead using 390mgs (1.5mmols) of 3-(5,6,7,8-tetrahydro-5,5,8,8-tetrameth- yl-naphth-2-yl)but-2(Z)-en-1-ol (Compound F), 1. 125g (7.5mmols) of samarium, 203mgs (0.75mmol) of mercuric chloride and 2.01g (7.5mmols) of diiodomethane title compound was obtained as a colorless oil.

PMR (CDCl3) : 8 0.59 (1H, t, j=5.4Hz), 1.12 (1H, dd, j=4.7, 8.9Hz), 1.27 (6H, s), 1.29 (6H, s), 1.40-1.48 (1H, m), 1.46 (3H, s), 1.68 (4H, s), 3.65-3.78 (1H, m), 3.85-3.92 (1H, m), 7.02 (1H, dd, j=2.1, 8.2Hz), 7.18 (1H, d, j=2.1Hz), 7.23 (1H, d, j=8.2Hz), Ethyl 3,7-dimethyl,6(RS)7(RS) methano-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl ),2(Z),4(E)- heptadienoate (Compound 3) and Ethyl 3,7-dimethyl,6(RS),7(RS) methano-7-(5,5,8 8-tetramethvl-5.6,7,8-tetrahydronaphth-2-vl?*2(E)4(E)

heptadienoate (Compound 4) Employing the same general procedure as used for the preparation of ethyl 3,7-dimethyl,6(RS),7(SR) <BR> <BR> <BR> <BR> methano-7-(5,6,7,8-tetrahydro-5 ,5,8,8-tetramethyl-naphth-2-yl) ,2(E),4(E)- heptadienoate (Compound 1), but instead using 300mgs (1.lmmols) of 3-methyl- 2(RS),3(RS)-methano-3[5,6,7,8-tetrahydro-5,5,8,8-tetra- methyl-naphth-2-yl]propan-1-ol (Compound G), the starting compound was converted to the isomeric title compounds in the ratio of 4 (Compund 4): 1 (Compound 3).

Ethvl 3,7-dimethyl,6(RS),7(RS) methano-7-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydronaphth-2-yl),2(Z),4(E)-heptadienoate (Compound 3) PMR (CDCl3) : 8 0.96 (1H, t, j=5.2Hz), 1.28 (6H, s), 1.29 (6H, s), 1.29 (3H, t, j=7.5Hz), 1.45 (3H, s), 1.51(1H, dd, j=4.9, 8.6Hz), 1.68 (4H, s), 1.88-1.98 (1H, m), 2.03 (3H, s), 4.28 (2H, q, j=7.5Hz), 5.59 (1H, s), 6.04 (1H, dd, j=9.0, 15.7Hz), 7.01 (1H, dd, j=2.0, 8.2Hz), 7.17 (1H, d, j=2.0Hz), 7.23 (1H, d, j=8.2Hz), 7.77 (1H, d, j=15.7Hz).

Ethvl 3,7-dimethyl,6(RS),7(RS) methano-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl )-2(E),4(E)- heptadienoate (Compound 4) PMR (CDCl3) : 8 0.94 (1H, t, j=5.5Hz), 1.27 (6H, s), 1.29 ((6H, s), 1.29 (3H, t, j=7.1Hz), 1.45 ( 3H, s), 1.51(1H, dd, j=4.9, 8.5Hz), 1.68 (4H, s), 1.78-1.88 (1H, m), 2.31 (3H, s), 4.17 (2H, q, j=7.1Hz), 5.72 (1H, s), 6.01 (1H, dd, j=9.0, 15.4Hz), 6.28 (1H, d, j=15.4Hz), 7.00 (1H, dd, j=2.1, 8.3Hz), 7.17 (1H, d, j=2.1Hz), 7.23 (1H, d, j=8.3Hz).

3,7-Dimethyl,6(RS),7(RS) methano-7-(5,5,8,8-tetrameth- yl-5,6,7,8-tetrahydronaphth-2-yl),2(Z),4(E)-heptadienoic acid (Compound 5) Employing the same general procedure as used for the preparation of 3,7-dimethyl,6(RS),7(SR) methano-7-(5,5,8,8- tetramethyl-5,6,7,8-tetrahydronaphth-2-yl),2(E),4(E)-heptadi enoic acid

(Compound 2), but instead using 30mgs of ethyl 3,7-dimethyl,6(RS),7(RS) methano-7-(5 ,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphth-2-yl), 2(Z),4(E)-heptadienoate (Compound 3), and LiOH in water (1M solution, lml), THF (2ml), methanol (2ml) the title compound was obtained as a white solid (21mgs).

PMR (CDCl3) ; 8 0.98 (1H, t, j=5.SHz), 1.28 (6H, s), 1.29 (3H, s), 1.30 (3H, s), 1.46 (3H, s), 1.54 (1H, dd, j=4.9, 8.6Hz), 1.68 (4H, s), 1.89-1.97 (1H, m), 2.06 (3H, s), 5.61(111, s), 6.09 (1H, dd, j=9.2, 15.7Hz), 7.01 (1H, dd, j=2.1, 8.2Hz), 7.17 (1H, d, j=2.1Hz), 7.24 (1H, d, j=8.2Hz), 7.74 (1H, d, j=15.7Hz).

3,7-Dimethyl,6(RS),7(RS) methano-7-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydronaphth-2-yl),2(E),4(E)-heptadienoic acid (Compound 6) Employing the same general procedure used for the preparation of 3,7-dimethyl,6(RS),7(SR) methano-7-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydronaphth-2-yl),2(E),4(E)-heptadienoic acid (Compound 2), but instead using 100mgs of ethyl 3,7-dimethyl,6(RS),7(RS) methano-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphth-2-y l) ,2(E) ,4(E)- heptadienoate (Compound 4), and LiOH in water (1M solution, 2ml), T11F (4ml), methanol (2ml) gave the title compound was obtained as a white solid.

PMR (CDCl3) : 8 0.95 (111, t, j=5.4Hz), 1.27 (6H, s), 1.28 (3H, s), 1.29 (3H, s), 1.45 (3H, s), 1.52 (1H, dd, j=5.0, 8.4Hz), 1.68 (4H, s), 1.80-1.89 (1H, m), 5.74 (1H, s), 6.07 (1H, dd, j=9.2, 15.4Hz), 6.32 (1H, d, j=15.4Hz), 7.00 (1H, dd, j=2.0, 8.3Hz), 7.16 (1H, d, j=2.0Hz), 7.24 (111, d, j=8.3Hz).

Ethyl 2-[5,5,8 8-tetramethyl-5,6,7,8-tetrahydronaphth- 2-yl]benzoate (Compound H) To magnesium (180mgs, 7.5mmols) in T11F (3ml) was added a solution of 2-bromo-5,5,8,8-tetramethyl- 5,6,7,8-tetrahydronaphthalene

(200mgs) in T11F (5ml) followed by 1,2-dibromoethane (94mgs, 0.5mmol). The mixture was stirred for 15 mins, then another portion of 2-bromo-5,5,8, 8-tetramethyl-5, 6,7, 8-tetrahydronaphthalene (1. 14g, Smmols) in T11F (10ml) was added. The mixture was stirred for 15 mins at room temperature, and refluxed for 1 h. ZnCl2 (680mgs, 5mmols) was added, stirred for 40mins, and to the white precipitate. ethyl-2-bromobenzoate (1.09g) in T11F (5ml) was added, immediately followed by addition of Ni(PPh2CH2CH2)Cl2 (26 mgs, 0.05 mmols). The mixture was stirred at room temperature for 16h. The reaction mixture was diluted with diethyl ether : ethylacetate (1:1, a total of 180ml), the organic phase was washed with water (10ml), brine (10ml) NaHCO3 (10ml) and brine (10ml), dried (MgSO4) and the solvent was removed under reduced pressure. Silicagel chromatography (5% ethyl acetate in hexane) followed by HPLC purification of the crude material gave the title compound as a colorless oil.

PMR (CDCl3) : 8 0.89 (3H, t, j=7.1Hz), 1.29 (6H, s), 1.31 (6H, s), 4.04 (2H, q, j=7.1Hz), 7.09 (1H, dd, j=2.0, 8.1Hz), 7.22 (1H, d, j=2.0Hz), 7.33 (1H, d, j=8.1Hz), 7.40 (2H, d, j=6.9Hz), 7.46-7.55 (1H, m), 7.76 (1H, d, j=7.1Hz).

2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)benzyla lcohol (Compound I) Employing the same general procedure as used for the preparation of 3-(5,5,8, 8-tetramethyl-5, 6,7, 8-tetrahydronaphth- 2-yl)but-2(Z)-en-1-ol (Compound C), but instead using 420mgs (1.25mmols) ethyl 2-[5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth- 2-yl]benzoate (Compound H) and 6 mmols of diisobutylaluminiumhydride the title compound was obtained as a white solid. PMR (CDCl3): 6 1.36 (6H, s), 1.39 (6H, s), 1.79 (4H, s), 4.67 (2H, s), 7.17 (1H, d, j=7.9Hz), 7.34-7.44 (soh, m), 7.55-7.61 (1H, m).

Ethyl 3-methyl-5-[2-(5,5,8,8,-tetramethyl-5.6,7,8-tetrahydronaphth -

2-yl)phenyl] pent-2(E) 4(E)-dienoate (Compound 7) and Ethyl 3-methyl-5-[2-(5,5,8,8,-tetramethyl-5,6,7,8-tetrahydronaphth -2-yl)phenyl} pent-2(Z),4(E)-dienoate (Compound 8) Employing the same general procedure as used for the preparation of ethyl 3,7-dimethyl,6(RS),7(SR) methano-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro- naphth-2-yl),2(E),4(E)-heptadienoate (Compound 2), but instead using 292mgs (lmmol) of 2-[5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth- 2-yl]benzylalcohol (Compound I), the starting material was converted to the isomeric title compounds in the ratio of 8 (Compound 7): 1 (Compound 8).

Compound 7: PMR (CDCl3) : 8 1.25 (6H, s), 1.28 (3H, t, j=7.1Hz), 1.32 (6H, s), 1.70 (4H, s), 2.22 (3H, brs), 4.16 (2H, q, j=7.1Hz), 5.87 (1H, brs), 6.74 (1H, d, j=16.1Hz), 7.01 (1H, d, j=16.1Hz), 7.11(1H, dd, j=1.8, 7.9Hz), 7.22 (1H, d, j=1.8Hz), 7.30-7.38 (4H, m), 7.59-7.69 (1H, m).

Compound 8: PMR (CDCl3) : 8 1.29 (6H, s), 1.33 (3H, t, j=7.2Hz), 1.35 (6H, s), 1.73 (4H, s), 1.96 (3H, s), 4.22 (2H, q, j=7.2Hz), 5.71(111, s), 7.03 (1H, d, j=16.3Hz), 7.15 (1H, dd, j=2.0, 8.1Hz), 7.26 (1H, d, j=2.0Hz), 7.32-7.39 (4H, m), 7.80-7.88 (1H, m), 8.39 (1H, d, j=16.3Hz).

3-Methyl-5-[2-(5,5,8,8,-tetramethyl-5,6,7,8-tetrahydronap hth-2-yl)phenyl] pent-2(E)4(E)-dienoic acid (Compound 9) Employing the same general procedure used for the preparation of 3,7-dimethyl,6(RS),7(SR) <BR> <BR> <BR> <BR> methano-7- (5,5,8,8-tetramethyl-5,6,7, 8-tetrahydronaphth-2-yi),2(E) ,4(E)- heptadienoic acid (Compound 2), but instead using 100mgs of ethyl 3-methyl-5-[2-(5,5,8,8,-tetramethyl-5,6,7,8-tetrahydronaphth -2-yl)phenyl] pent-2(E),4(E)dienoate (7) and LiOH in water (1M solution, 1.5ml), THF (2ml), methanol (2ml) the title compound was obtained as a white

solid.

PMR (CDCl3) : 81.28 (6H, s), 1.35 (6H, s), 1.73 (4H, s), 2.26 (3H, s), 5.93 (1H, s), 6.79 (1H, d, j=16.1Hz), 7.10 (1H, d, j=16.1Hz), 7.14 (1H, dd, j=1.8, 8.2Hz), 7.25 (1H, d, j=1.8Hz), 7.34-7.41 (4H, m), 7.64-7.71 (111, m).

3-Methyl-5-(2-(5,5,8,8,-tetramethyl-5,6,7,8- tetrahydronaphth- 2-yl)phen-1-yl) pent-2(Z),4(E)-dienoic acid (Compound 10) Employing the same general procedure as used for the preparation of 3,7-dimethyl,6(RS),7(SR) <BR> <BR> <BR> methano-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl ),2(E),4(E)- heptadienoic acid (Compound 2), but instead using 20mgs of ethyl <BR> <BR> <BR> 3-methyl-5-[2-(5,5,8,8,-tetramethyl-5,6,7,8-tetrahydronaphth -2-yl)phenyl] pent-2(Z),4(E)dienoate (Compound 8) and LiOH in water (1M solution, 0.5ml), T11F (2ml), methanol (2ml) the title compound was obtained as a white solid.

PMR (CDCl3) : 8 1.30 (6H, s), 1.35 (6H, s), 1.74 (4H, s), 2.00 (3H, s), 5.75 (1H, s), 7.09 (1H, d, j=15.9Hz), 7.15 (1H, dd, j=1.7, 8.2Hz), 7.32-7.41 (4H, m), 7.78-7.83 (1H, m), 8.32 (1H, d, j=15.9Hz).

Ethvl 3-[3,5,5,8,8,-pentamethyl-5,6,7,8- tetrahydronaphth-2-yl]propiolate (Compound J) Employing the same general procedure as used for the preparation of ethyl 3-[5,5,8,8,-tetramethyl-5,6,7,8-tetrahydronaphth- 2-yl]propiolate (Compound A), but instead using 1.9g of (3-methyl-5,5,8,8,-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl )ethyne, 940mgs (lOmmols) of methylchloroformate and 8.8mmols of n-butyllithium the title compound was obtained as an oil.

PMR (CDCl3) : a 1.26 (6H, s), 1.27 (6H, s), 1.67 (4H, s), 2.43 (3H, s), 3.85 (3H, s), 7.16 (1H, s), 7.51 (1H, s).

Methvl 3-[3,5,5,8,8-pentamethyl-5,6,7,8- tetrahydronaphth-2-yl]but- 2(Z)-enoate (Compound K)

Employing the same general procedure as for the preparation of ethyl 3-[5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl]but-2(Z )-enoate (Compound B), but instead using 2.05gs (6.4mmols) of methyl 3-[3,5,5,8,8,-pentamethyl-5,6,7,8-tetrahydronaphth-2- yl]propiolate (Compound J), 2.lgs (10.24mmols) of CuBr.DMS, 18mmols of methyl lithium in diethyl ether and maintaining the temperature at -78°C the title compound was obtained as a white solid.

PR (CDCl3) : 1.24 (6H, s), 1.28 (6H, s), 1.67 (6H, s), 2.12 (3H, s), 2.15 (3H, s), 3.50 (3H, s), 5.96 (1H, s), 6.86 (1H, s), 7.08 (1H, s).

3- [3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphth-2-yl]but-2(Z )-en- 1-ol (Compound L) Employing the same general procedure as used for the preparation of 3- (5,5,8, 8-tetramethyl-5, 6, 7,8-tetrahydronaphth- 2-yl)but-2(Z)-en-1-ol (Compound C), but instead using 1.85gs (6.1mmols) of methyl 3-[3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphth- 2-yl]but-2(Z)-enoate (Compound K) and 15mmols of diisobutylaluminiumhydride the title compound was obtained as a white solid.

PMR (CDCL3) : 81.25 (6H, s), 1.28 (6H, s), 1.67 (4H, s), 2.00 (3H, s), 2.16 (3H, s), 3.84 (2H, d, j=7.1Hz), 5.73 (1H, dt, j=1.6, 7.1Hz), 6.90 (1H, s), 7.08 (1H, s). <BR> <BR> <BR> <P>3-Methvl-2(RS) ,3(SR)-methano-3 [3.5.5.8.8-pentamethvl-5.6.7.8-tetrahvdr onaphth-2-vl3propan-1-ol (Compound M) Employing the same general procedure as used for the preparation of 3-methyl-2(RS),3(SR)-methano-3[5,5,8,8-tetramethyl- 5,6,7,8-tetrahydronaphth-2-yl]propan- 1-ol (Compound D), instead using 1.1gs (4mmols) of 3-[3,5,5,8,8-pentamethyl-5,6,7,8- tetrahydronaphth-2-yl]but-2(Z)-en- 1-ol (Compound L), 3.1g (20.6mmols) of samarium, 450mgs (1.7mmol) of mercuric chloride and 5.8g (21.6mmols) of diiodomethane the title compound was obtained as a

colorless oil.

PMR (CD3COCD3) : 8 0.60 (1H, brs), 0.80 (1H, brs), 1.23 (9H,s), 1.24 (311, s), 1.64 (411, s), 1.63-1.67 (1H, m), 2.33 (311, s), 2.85 (311, s), 3.34-3.48 (211, m), 7.06 (1H, s), 7.25 (1H, brs).

Ethvl 3,7-dimethyl,6(RS),7(SR) methano-7-(3,5,5,8,8-pentamethyl- 5.6.7,8-tetrahvdronaphth-2-vl? 2(E) 4(E)-heptadienoate (Compound 11) and Ethvl 3,7-dimethyl,6(RS),7(SR) methano-7-(3.5.5.8.8-pentamethvl- 5,6,7,8-tetrahydronaphth-2-yl), 2(Z) 4(E)-heptadienoate (Compound 12) Employing the same general procedure as used for the preparation of ethyl 3,7-dimethyl,6(RS),7(SR) methano-7-(5,5,8,8- tetramethyl-5,6,7,8- tetrahydronaphth-2-yl),2(E),4(E)-heptadienoate (Compound 2), but instead using 390mgs (1.4mmols) of 3-methyl-2(RS),3(RS)-methano-3[3,5,5,8,8-pentamethyl- 5,6,7,8-tetrahydronaphth-2-yl]propan-1-ol (Compound M), the starting material was converted to the isomeric title compounds in the ratio of 8 (Compund 11): 1(Compound 12).

Compound 11: PMR (CDCl3) : 8 0.96 (1H, brs), 1.20 (1H, brs), 1.25 (311, s), 1.26 (311, s), 1.27 (611, s), 1.29 (311, t, j=7.1Hz), 1.37 (311, s), 1.66 (411, s), 1.70-1.80 (1H, m), 2.04 (311, brs), 2.31 (311, brs), 4.16 (2H, q, j=7.1Hz), 5.30 (1H, brs), 5.66 (1H, brs), 6.25 (1H, d, j=15.5Hz), 7.04 (1H, s), 7.07 (1H, brs).

Compound 12: PMR (CDCl3) : 8 0.95 (1H, brs), 1.19 (1H, brs), 1.23 (311, s), 1.25 (911, s), 1.30 (311, t, j=7.1Hz), 1.35 (311, s), 1.64 (411, s), 1.71 (3H, brs), 1.80-1.90 (1H, m), 2.31(311, BRS), 4.17 (211, q, j=7.1Hz), 5.31 (1H, brs), 5.49 (1H, s), 7.02 (1H, s), 7.08 (1H, brs), 7.78 (1H, d, j=15.6Hz).

3,7-Dimethyl,6(RS),7(SR) methano-7-(3,5,5,8,8-pentamethyl-5,6,7,8- tetrahydronaphth-2-yl) 2(E) 4 (E)-heptadienoic acid (Compound 13)

Employing the same general procedure as used for the preparation of 3,7-dimethyl,6(RS),7(SR) methano-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl ),2(E),4(E)- heptadienoic acid (Compound 2), but instead using 100mgs of ethyl 3,7-dimethyl,6(RS),7(RS) methano-7-(3,5,5,8,8-pentamethyl-5,6,7,8- tetrahydronaphth-2-yl),2(E),4(E)-heptadienoate (Compound 4) and LiOH in water (1M solution, lml), T11F (4ml), methanol (2ml) the title compound was obtained as a white solid.

PMR (CD3COCD3) : a 1.01(111, brs), 1.18 (1H, s), 1.21 (3H, s), 1.23 (3H, s), 1.24 (6H, s), 1.33 (3H, s), 1.64 (4H, s), 1.70-1.86 (1H, m), 1.97 (3H, brs), 2.29 (3H, brs), 5.31 (1H, brs), 5.68 (1H, s), 6.31 (1H, d, j=15.8Hz), 7.09 (2H, s).

3,7-Dimethyl,6(RS), 7(SR? methano-7-(3*5 5,8,8-pentamethyl-5,6,7,8-tetrahydronaphth-2-yl), .2(Z? ,4( E)-heptadienoic acid (Compound 14) Employing the same general procedure as used for the preparation of 3,7-dimethyl,6(RS) ,7(SR) <BR> <BR> <BR> methano-7- (5 ,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl) ,2(E) ,4(E)- heptadienoic acid (Compound 2), but instead using 12mgs of ethyl 3,7-dimethyl,6(RS),7(RS) methano-7-(3,5,5,8,8-pentamethyl-5,6,7,8- tetrahydronaphth-2-yl),2(Z),4(E)-heptadienoate (Compound 12) and LiOH in water (1M solution in water 0.4ml) the title compound was obtained as a white solid.

PMR (CDCl3) : 8 1.01 (1H, brs), 1.20 (1H, s), 1.24 (12H, s), 1.35 (3H, s), 1.66 (4H, s), 1.79-1.89 (1H, m), 2.30 (3H, brs) 2.83(3H, brs), 5.30 (111,brs), 5.52 (1H, s), 7.10 (2H, brs), 7.81(1H, d, j=16.4Hz).

Methyl 3-(4,4-dimethyl-thiochroman-6-yl)propiolate (Compound N) Employing the same general procedure as used for the preparation of ethyl 3-(5,5,8,8,-tetramethyl-5,6,7,8- tetrahydronaphth-2-yl)propiolate (Compound A), but instead using 2.0g

(1 Ommols) of (4,4-dimethyl-thiochroman-6-yl)ethyne, 2g (21. 3mmols) of methylchloroformate and 11 mmols of n-butyl lithium the title compound was obtained as a yellow solid. <BR> <BR> <BR> <P>PMR (CDCl3) : a 1.31(611, s), 1.90-1-1.97 (2H, m), 3.00-3.07 (2H, m), 3.83 (3H, s), 7.07 (1H, d, j=8.1Hz), 7.22 (1H, dd, j=1.8, 8.1Hz), 7.57 (1H, d, j=1.8Hz).

Methyl 3-[4,4-dimethyl-thiochroman-6-yl]but-2(Z)-enoate (Compound O) Employing the same general procedure as for the preparation of ethyl 3-[5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl]but-2(Z )-enoate (Compound B), but instead using 1.6g (6.lmmols) of methyl 3-[4,4-dimethyl-thiochroman-6-yl]propiolate (Compound N), 2.1g (10.24mmols) of CuBr.DMS, 18mmols of methyl lithium in ether and maintaining the temperature at -78°C, the title compound was obtained as a colorless oil.

PMR (CDCl3): #1.33 (6H, s), 1.97 (2H, t, j=6.0Hz), 3.03 (2H, t, j=6.0Hz), 3.58 (3H, s), 5.87 (1H, s), 6.93 (1H, dd, j=1.9, 8.1Hz), 7.05 (1H, d, j=8.1Hz), 7.24 (111, d, j=1.9Hz).

3-[4,4-Dimethyl-thiochroman-6-yl]but-2(Z)-en-1-ol (Compound P? Employing the same general procedure used for the preparation of 3- [5,5,8, 8-tetramethyl-5, 6,7, 8-tetrahydronaphth-2-yl]but-2(Z) -en- 1-ol (Compound C), but instead using 1.3g (4.7mmols) of methyl 3- [4,4-dimethyl-thiochroman-6-yl]but-2(Z)-enoate (Compound 0) and 15mmols of diisobutylaluminiumhydride the title compound was obtained as a colorless oil.

PMR (CDCl3) : â 1.34 (6H, s), 1.95-2.00 (2H, m), 2.08 (3H, s), 3.01-3.05 (2H, m), 4.10 (2H, d, j=7.0Hz), 5.67 (1H, d, j=7.0Hz), 6.87 (1H, dd, j=2.0, 8.1Hz), 7.05 (1H, d, j=8.1Hz), 7.17 (1H, d, j=2.0Hz).

3-Methyl-2(RS),3(SR)methano-3 [4,4-dimethyl-thiochro- man-6-vl]propan-1-ol (Compound O)

Employing the same general procedure as used for the preparation of 3-methyl-2(RS),3(SR)-methano-3[5,5,8,8-tetramethyl- 5,6,7,8-tetrahydronaphth-2-yl]propan- l-ol (Compound D), but instead using 1.23g (4.5mmols) of 3-[4,4-dimethyl-thiochroman-6-yl] but-2(Z)-en-1-ol (Compound P), 3.95g (26.3mmols) of samarium, 520mgs (1.92mmols) of mercuric chloride and 6.95g (25.9mmols) of diiodomethane the title compound was obtained as a colorless oil.

PMR (CDCl3) : #0.75-0.85 (2H, m), 1.20-1.31 (1H, m), 1.32 (6H, s), 1.96 (2H, t, j=5.9Hz), 3.01 (2H, t, j=5.9Hz), 3.15-3.29 (2H, m), 7.00 (2H, s), 7.31 (1H, s).

Ethyl 3,7-dimethyl,6(RS),7(SR) methano-7-(44-dimethvl-thiochrman-6-yl)2(E)4(E)-heptadienoat e (Compound 15) and Ethyl 3,7-dimethyl,6(RS),7(SR) methano-7-(4,4-dimethyl-thiochroman-6-yl) 2(Z),4(E)-heptadienoate (Compound 16) Employing the same general procedure as used for the preparation of ethyl 3,7-dimethyl,6(RS),7(SR) methano-7-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydronaphth-2-yl),2(E),4(E)-heptadienoate (Compound 2), but instead using 245mgs (0.95mmol) of 3-methyl-2(RS),3(RS)-methano-3 [4,4-dimethyl-thiochro- man-6-yl]propan-1-ol (Compound Q), the starting material was converted to the isomeric title compounds in the ratio of 4 (Compound 15): 1 (Compound 16).

Compound 15: PMR (CDCl3) : 8 1.09 (1H, t, j=5.1Hz), 1.17 (1H, dd, j=5.7, 8.2Hz), 1.25 (3H, s), 1.27 (3H, t, j=7.1Hz), 1.32 (3H, s), 1.39 (3H, s), 1.67-1.76 (1H, m), 1.92-1.98 (2H, m), 2.01 (3H, s), 2.98-3.04 (2H, m), 4.14 (2H, q, j=7.1Hz), 5.22 (1H, dd, j=10.0, 15.5Hz), 5.64 (1H, s), 6.20 (1H, d, j=15.5Hz), 6.95 (1H, dd, j=1.8, 8.1Hz), 7.01 (1H, d, j=8.1Hz), 7.20 (1H,

d, j=1.8Hz).

Compound 16: PMR (CD3COCD3) : 8 1.17-1.22 (2H, m), 1.22 (311, t, j=7.1Hz), 1.26 (311, s), 1.30 (311, s), 1.40 (311, s), 1.67 (311, s), 1.77-1.86 (1H, m), 1.90-1.96 (211, m), 2.97-3.03 (211, m), 4.09 (2H, q, j=7.1Hz), 5.27 (1H, dd, j=9.9, 15.9Hz), 5.47 (1H, s), 6.95 (1H, d, j=8.2Hz), 6.98 (1H, dd, j=1.7, 8.2Hz), 7.74 (1H, d, j=15.9Hz).

3,7-Dimethy1,6(RS),7(SR) methano-7-(4,4-dimethyl-thiochroman-6-yl),2(E),4(E)-heptadie noic acid (Compound 17) Employing the same general procedure as used for the preparation of 3,7-dimethyl,6(RS),7(SR) <BR> <BR> <BR> methano-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl ),2(E),4(E)- heptadienoic acid (Compound 2), but instead using 100mgs (0.28mmol) of ethyl 3,7-dimethyl,6(RS),7(RS) methano-7-(4,4-dimethyl-thiochroman-6-yl) ,2(E) ,4(E) -heptadienoate (Compound 15) and LiOH in water (1M solution in water, 0.4ml) the title compound was obtained as a white solid.

PMR (CDCl3) : 8 1.10 (1H, t, j=4.9Hz), 1.19 (1H, dd, j=4.9, 8.2Hz), 1.25 (311, s), 1.32 (311, s), 1.4 (311, s), 1.69-1.79 (1H, m), 1.95 (2H, t, j=6.5Hz), 2.01(311, s), 3.01(211, t, j=6.5Hz), 5.27 (1H, dd, j=10.0, 15.5Hz), 5.66 (1H, s), 6.24 (1H, d, j=15.5Hz), 6.95 (1H, dd, j=1.8, 8.1Hz), 7.01(111, d, j=8.1Hz), 7.20 (1H, dd, j=1.8Hz).

3,7-DimethyL6(RS) ,7(SR) methano-7-(4,4-dimethyl-thiochroman-6-yl) 2(Z) 4(E) -heptadienoic acid (Compound 18) Employing the same general procedure as used for the preparation of 3,7-dimethyl,6(RS),7(SR) <BR> <BR> <BR> methano-7- (5,5,8, 8-tetramethyl-5, 6,7, 8-tetrahydronaphth-2-yl),2(E),4(E)- heptadienoic acid (Compound 2), but instead using 30mgs (0.08mmol)

of ethyl 3,7-dimethyl,6(RS),7(RS) methano-7-(4,4-dimethyl-thiochr- man-6-yl),2(Z),4(E)-heptadienoate (16) and LiOH in water (1M solution in water 0.5ml) the title compound was obtained as a white solid.

PMR (CDCl3) : 8 1.12 (1H, t, j=4.9Hz), 1.22 (1H, dd, j=4.9, 8.1Hz), 1.28 (3H, s), 1.34 (3H, s), 1.41 (3H, s), 1.75 (3H, s), 1.82-1.92 (1H, m), 1.95-2.01 (2H, m), 3.03 (2H, t, j=5.9Hz), 5.28 (1H, dd, j=10.1, 15.7Hz), 5.54 (1H, s), 6.97 (1H, dd,j=1.8, 8.0Hz),7.03 (1H, d, j=8.0Hz), 7.24 (1H, d, j=1.8Hz), 7.73 (1H, d, j=15.7Hz.

Methvl 3-(44-dimethyl-chroman- 6-vl)propiolate (Compound R) Employing the same general procedure as used for the preparation of ethyl 3-[5,5,8,8,-tetramethyl-5,6,7,8-tetrahydro- naphth-2-yl]propiolate (Compound A) but instead using 1.86 g (10 mmols) of [4,4-dimethyl-chroman-6-yl] ethyne, 2g (21.3 mmols) of methylchloroformate and 11 mmols of n-butyllithium the title compound was obtained as a yellow solid.

PMR (CDCl3): 8 1.32 (6H, s), 1.82 (2H, t, j = 5.6 Hz, 3.82 (3H, s), 4.22 (2H, t, j = 5.6 Hz), 6.75 (1H, d, j = 8.6 Hz), 7.30 (1H, dd, j = 2.0, 8.6 Hz), 7.53 (1H, d, 2.0 Hz).

Methvl 3-[4,4-dimethyl-chroman-6-vl]but-2(Z?-enoate (Compound S) Employing the same general procedure as for the preparation of ethyl 3-[5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphth-2-yl]but-2( Z)-enoate (Compound B) but instead using 1.4 g (5.7 mmols) of methyl 3-(4,4-dimethyl-chroman-6-yl]propiolate (Compound R), 2.1 g (10.24 mmols) of CuBr.DMS, 18 mmols of methyllithium in ether and maintaining the temperature at -78°C the title compound was obtained as a colorless oil.

PMR (CDCl3): 8 1.34 (6H, s), 1.85 (2H, t, j = 5.4 Hz), 2.18 (3H, s), 3.58 (3H, s), 4.20 (2H, t, j = 5.4 Hz), 5.85 (1H, s), 6.76 (1H, d, j = 8.5 Hz), 7.00 (1H, dd, j = 2.2 Hz, 8.5 Hz).

3-[4,4-Dimethyl-chroman-6-yl]but-2(Z)-en-1-ol (Compound T) Employing the same general procedure used for the preparation of 3-[5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphth-2-yl]but-2( Z)-en- 1-ol (Compound C) but instead using 270 mgs (1.04 mmols) of methyl 3-[4,4-dimethyl-chroman-6-yl]but-2(Z)-enoate (Compound S) and 4 mmols of diisobutylaluminiumhydride the title compound was obtained as a colorless oil.

PMR (CDCl3): 6 1.34 (6H, s), 1.85 (2H, t, j = 5.4 Hz), 2.08 (3H, s), 4.12 (2H, d, j = 6.2 Hz), 4.20 (2H, d, j = 5.4 Hz), 5.67 (1H, t, j = 6.2 Hz), 6.75 (1H, d, j = 8.3 Hz), 6.92 (1H, dd, j = 2.1, 8.3 Hz), 7.08 (1H, d, j = 2.1 Hz).

3-Methvl-2(RS) 3(SR)-methano-3 [4,4-dimethyl-chroman-6-yl]propan-1-ol (Compound U) Employing the same general procedure as used for the preparation of 3-methyl-2(RS),3(SR)-methano- 3 [5,5,8-8-tetramethyl-5,6,7,8-tetrahydro-naphth-2-yl]propan- 1-ol (Compound D) but instead using 230 mgs (1 mmol) of 3-[4,4-dimethyl-chroman-6-yl] but-2(Z)-en-1-ol (Compound T) 750 mgs (5 mmols) of samarium, 130 mgs (0.5 mmol) of mercuricchloride and 1.35 g (5 mmols) of diiodomethane the title compound was obtained as a colorless oil.

PMR (CDCl3): â 0.74 - 0.83 (2H, m), 1.22 - 1.27 (1H, m), 1.33 (3H, s), 1.37 (3H, s), 1.83 (2H, t, j = 5.4Hz), 3.12- 3.34 (2H, m), 4.17 (2H, d, j = 5.4 Hz), 6.72 (1H, d, j = 8.3 Hz), 7.02 (1H, dd, j = 2.2, 8.3 Hz), 7.21 (1H, d, j = 2.2 Hz). <BR> <BR> <BR> <BR> <P>Ethyl 3,7-dimethyl,6(RS),7(SR) 37-dimethyl6(RS) 7(SR) <BR> <BR> <BR> <BR> <BR> <BR> <BR> methano-7- (44-dimethyl-chroman-6-yl) 2(E) 4 (E)-heptadieonate (Compound 19) and ethyl 3,7-dimethyl,6(RS),7(SR) methano-7-(4,4-dimethyl-chroman-6-yl) 2(Z) 4(E) -heptadienoate (Compound 20)

Employing the same general procedure as used for the preparation of ethyl 3,7-dimethyl,6(RS),7(SR) methano-7(5,5,8,8- tetramethyl-5 ,6,7,8-tetrahydro- naphth-2-yl),2(E),4(E)-heptadienoate (Compound 1) but instead using 110 mgs (0.5 mmol) of 3-methyl-2(RS),3(RS)-methano-3[4,4-diimethyl-chroman-6-yl]pr o- pan-1-ol (Compound U) isomeric title compounds were obtained in the ratio of 4 (Comopund 19): 1 (Compound 20) Compound 19: PMR (CDCl3): â 1.07 (1H, t, j = 4.7 Hz), 1.15 (1H, dd, j = 4.7, 8.2 Hz), 1.26 (311,), 1.26 (311, t, j = 7.1 Hz), 1.31(311, s), 1.38 (311, s), 1.65 - 1.74 (1H, m), 1.81 (2H, t, j = 5.4 Hz), 1.99 (311, s), 4.13 (211, q, j = 7.1 Hz), 4.17 (2H, t, j = 5.4 Hz), 5.22 (1H, dd, j = 9.9, 15.6 Hz), 5.63 (1H, s), 6.19 (1H, d, j = 15.6 Hz), 6.70 (1H, d, j = 8.3 Hz), 6.96 (1H, dd, j = 2.2, 8.3 Hz), 7.10 (1H, d, j = 2.2 Hz). Compound 20: PMR (CDCl3): â 1.07 (1H, t, j = 4.7 Hz), 1.17 (1H, dd, j = 4.7, 8.2 Hz), 1.25 (311, s), 1.29 (311, t, j = 7.1 Hz), 1.31(311, s), 1.37 (311, s), 1.68 (311, brs), 1.75 - 1.85 (311, m), 4.12 - 4.21(411, m), 5.21 (1H, dd, j = 8.9, 15.8 Hz), 5.47 (1H, s), 6.70 (1H, d, j = 8.3 Hz), 6.97 (1H, dd, j = 2.2, 8.3 Hz), 7.11(111, d, j = 2.2 Hz), 7.72 (1H, d, j = 15.8 Hz).

37-DimethyL6(RS? s7(SR? methano-7-(4 4-dimethyl-chroman-6-yl?*2(E) 4(E?-heptadienoic acid (Compound 21) Employing the same general procedure used for the preparation of 3,7-dimethyl,6(RS),7(SR) methano-7-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-naphth-2-yl),2(E),4(E)-heptadienoic acid (Comopund 2) but instead using 21 mgs (0.06 mmol) of ethyl 3,7-dimethyl,6(RS),7(RS) methano-7-(4,4-dimethyl-chroman-6-yl) ,2(E) ,4(E)-heptadienoate (Compound 19) and LiOH in water (1 M solution in water 0.4 ml) gave the title compound as a white solid.

PMR (CDCl3): â 1.10 (111, t, j = 4.9 Hz), 1.18 (111, dd, j = 4.9,

8.1 Hz), 1.26 (3H, s), 1.32 (3H, s), 1.40 (3H, s), 1.67 - 1.79 (1H, m), 1.82 (2H, t, j = 5.8 Hz), 2.00 (3H, s), 4.17 (2H, t, j = 5.8 Hz), 5.28 (1H, dd,j = 9.9, 15.4 Hz), 5.65 (1H, s), 6.22 (111, d, j = 15.4 Hz), 6.72 (1H, d, j = 8.3 Hz), 6.97 (1H, dd, j = 2.1 Hz, 8.3 Hz), 7.10 (1H, d, j = 2.1 Hz).

(-) 3-Methvl-2(R? 3(S?-methano-3-(S 5 8 8-tetramethvl-S 6 7 8- tetrahydronaphth-2-vl-)propan-1-ol (Compound Al) and (+) 3-Methvl- 2(S);3(R)-methano-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydron aphth-2-yl- )propan-1-ol (Compound A2) To a cold (0°C) solution of 3-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydronaphth-2-yl)but-2-(Z)-en- 1 -ol (Compound C, 920 mg, 3.6 mmol) in dichloromethane (18 mL) was added diethyl zinc (1M solution in heptane, 4 mL, 4 mmol) and stirred for 15 minutes. To this solution L (+) diethyl tartrate was added (neat) via syringe and drop- wise over 3 minutes. The mixture was stirred for 1 hour, then cooled to -25°C and another portion of diethyl zinc in heptane (1M solution, 8 mL) was added and the mixture was stirred for an additional 10 minutes. To this mixture diiodomethane (3.96 g, 14.9 mmol) (neat) was added. The mixture was stirred at -4°C for 4 days. The mixture was poured into ammonium chloride solution and diluted with ether (120 mL) and washed with 10% HCl, NaHCO3, brine, dried and the solvent was removed by evaporation. The mixture was purified by chromatography to obtain a mixture of enantiomeric cyclopropyl alcohols. This enantio selective cyclopropylation reaction is in analogy to the reactions described by Ukaji et al. Chemistry Letters: p 61-64 (1992).

Esterification: The enantiomeric cyclopropyl alcohols were then dissolved in dichloromethane (10 mL), pyridine (5 mL), N,N- dimethylaminopyridine (50 mg) was added and the mixture was cooled to 0°C. To this mixture was added (-) 1-(S)-camphanic chloride (1.57 g, 7.2 mmol) and heated to 70°C for overnight. After cooling to ambient

temperature the mixture was diluted with ether (120 mL), washed with water (10 mL), 10% HCl (20 mL), brine (10 mL), dried and the solvent was removed by distillation. The residual material was passed through a silicagel column to obtain a 10:1 ratio of two diastereomeric camphanoic ester derivatives. The major diastereomer (Compound A3) was recrystallized from hexane and the crystals were examined by single crystal X-ray crystallography that confirmed the absolute stereochemistry at C-2 as R and at C-3 as S.

The minor diastereomer (Compound A4) was obtained by purification with high pressure liquid chromatography on Partisil- 10-PAC preparative HPLC column, using 8% ethylacetate in hexane with RT of 128 mins for the major diastereomer and 137 mins for the minor diastereomer.

Major diastereomeric camphanoic ester (Compound A3): [a] 21D -10.7 (c, 0.005, CH2Cl2)- 1HNMR (CDC13): a 0.82-0.90 (m, 1H), 0.90-0.96 (m, 1H), 0.96 (s, 3H), 1.04 (s, 311), 1.22 (s, 311), 1.25 (s, 311), 1.26 (s, 311), 1.27 (s, 3H), 1.28 (s, 311), 1.28-1.40 (m, 1H), 1.38 (s, 3H), 1.62-1.75 (m, 1H), 1.66 (s, 411), 1.85-2.05 (m, 211), 2.30-2.42 (m, 1H), 3.74 (dd, J = 11.5, 7.7 Hz, 1H), 3.98 (dd, J = 11.5, 7.7 Hz, 1H), 7.04 (dd, J = 2.0, 8.0 Hz, 1H), 7.18 (s, 1H), 7.19 (d, J = 8.0 Hz, 1H).

Minor diastereomeric camphanoic ester (Compound A4): [a] 21D -5-4 (c, 0.007, CH2Cl2). lHNMR (CDC13): 8 0.82-0.89 (m, 1H), 0.91-0.98 (m, 1H), 0.94 (s, 311), 1.06 (s, 311), 1.12 (s, 311), 1.24 (s, 311), 1.26 (s, 3H), 1.26 (s, 311), 1.27 (s, 3H), 1.28-1.40 (m, 1H), 1.39 (s, 311), 1.65-1.73 (m, 1H), 1.67 (s, 411), 1.85-2.05 (m, 211), 2.35-2.45 (m, 1H), 3.76 (dd, J = 11.5, 7.7 Hz, 1H), 3.95 (dd, J = 11.5, 7.7 Hz, 1H), 7.04 (dd, J = 2.0, 8.0 Hz, 1H), 7.18 (s, 1H), 7.19 (d, J = 8.0 Hz, 1H).

Saponification: The major diastereomeric camphanoic ester obtained above (Compound A3) was dissolved in T11F (2 mL), MeOH (2 mL)

and LiOH (1M solution in water, 0.5 mL) and heated to 700C for 1 hour. The reaction mixture was diluted with water (5 mL), extracted with ether (3 x 30 mL), the organic layer was washed with water (10 mL), brine (10 mL), dried and the solvent was removed by evaporation.

The crude material was purified by column chromatography, and the levo rotatory title compound (Compound Al) was obtained as a colorless oil.

[a] 21D -22.7 (c, 0.023, CH2Cl2)- Similar process of saponification of the minor diastereomeric camphanoic ester (Compound A4) provided the dextro rotatory title compound (Compound A2) [a]D21 +21.80 (c = .0225g/mL, CH2Cl2) 1HNMR (CDCl3) for both enantiomers Al and A2: 8 0.76 (dd, J = 8.4, 4.8 Hz, 1H), 0.87 (t, J = 4.8 Hz, 1H), 1.27 (s, 6H), 1.28 (s, 6H), 1.25- 1.31 (m, 1H), 1.40 (s, 3H), 1.67 (s, 4H), 3.18 (dd, J = 11.6, 7.9 Hz, 1H), 3.31 (dd, J = 11.6, 7.9 Hz, 1H), 7.07 (dd, J = 2.0, 8.0 Hz, 1H), 7.22 (d, J = 8.0 Hz, 1H), 7.23 (s 1H).

3-Methvl-2(R),3(S )-methano-3- (5,5,8,8-tetramethvl-5,6,7,8- tetrahydronaphth-2-yl-)propanal (Compound A5) To a cold (-780C) solution of dimethylsulfoxide (DMSO) (400 mg, 5.5 mmol) in dichloromethane (10 mL), was added oxalyl chloride in dichloromethane (2M solution, 2 mL) drop wise (5 min). The mixture was stirred for 10 minutes. To this mixture a solution of 3-methyl- 2(R) ,3(S)-methano-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronapht h-2-yl- )propan-1-ol (Compound Al, 45 mg, 0.17 mmol) in dichloromethane (5 mL) was added drop-wise (3 min). The reaction was stirred for 20 minutes at -600C and triethylamine (1.5 g, 15 mmol) was added and the reaction mixture was warmed to 100C over a period of 30 minutes. The reaction mixture was diluted with water (15 mL), extracted with ether (3 X 30 mL), the ether layer was washed with water (10 mL) and brine (10

mL), dried and the solvent was removed by evaporation. The residual crude material was passed through silicagel column using 5% ethylacetate in hexane to obtain the title compound as a pale yellow oil that is not stable for a prolonged period of time. This unstable substance was used without further purification in the next step.

A similar procedure, starting with the dextro rotatory alcohol (Compound A2) provided the enantiomeric aldehyde 3-methyl- <BR> <BR> <BR> <BR> 2(S), 3(R)-methano-3-(5,5, 8, 8-tetramethyl-5, 6,7, 8-tetrahydronaphth-2-yl- )propanal (Compound A7).

(+) Ethyl 37-dimethyl-6(S) 7(S)-methano-7(5588-tetramethyl-5678- tetrahydronaphth-2-yl)-2(E),4(E)-heptadienoate (Compound A6) To a cold (-780C) solution of ethyl-diethylphosphono-3-methyl- 2(E)-butenoate (528 mg, 2 mmol) in T11F (5 mL) was added n-BuLi in hexane (1.6M solution, 1.3 mL, 2.0 mmol), and the mixture was stirred for 2 minutes. To this reaction mixture a solution of 3-methyl- <BR> <BR> <BR> <BR> 2(R),3(S)-methano-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydron aphth-2-yl- )propanal (Compound A5, 55mg crude material obtained in the reaction above) in T11F (2 mL) was added at -780C and stirred for 1 hour. The reaction was diluted with water (10 mL), extracted with ether (3 x 40 mL), washed with water (10 mL) and brine (10 mL), dried and the solvent was removed by evaporation. The product was purified by column chromatography (using 5% ethylacetate in hexane), followed by separation on a Partisil-lO-PAC, semi-preparatory HPLC column, using 1% ethylacetate in hexane to give the title compound as a colorless oil.

[a] 21D +82.33 (c, 0.014, CH2C12) A similar procedure conducted with the enantiomeric aldehyde, 3- methyl-2(S),3(R)-methano-3-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydronaphth-2-yl-)propanal (Compound A7) gave (-) ethyl 3,7- dimethyl-6(R),7(R)-methano-7(5,5,8,8-tetramethyl-5,6,7,8- tetrahydronaphth-2-yl)-2(E) ,4(E) -heptadienoate (Compound A8)

[a]D21 -80.80 (c = .0025g/mL, CH2C12) lHNMR (CDCl3 for both enantiomeric esters.: 8 1.11-1.20 (m, 2H), 1.21 (s, 3H), 1.28 (s, 9H), 1.28 (t, J=7.2 Hz, 3H), 1.43 (s, 3H), 1.68, (s, 4H), 1.68-1.80 (m, 1H), 1.99 (s, 3H), 4.15 (q, J= 7.2 Hz, 2H), 5.22 (dd, J = 9.9, 15.4 Hz, 1H), 5.63 (s, 1H), 6.20 (d, J = 15.4 Hz, 1H), 7.03 (dd, J = 1.9, 8.1 Hz, 1H), 7.14 (d, J = 1.9 Hz, 1H), 7.23 (d, J = 8.1 Hz, 1H).

(+) 3,7-Dimethvl-6(S ,7(S)-methano-7(5,5,8,8-tetramethvl-5,6, tetrahydronaphth-2-yl)-2(E)-4(E)-heptadienoic acid (Compound 2a) To a solution of (+) ethyl 3,7-dimethyl-6(S),7(S)-methano- 7(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)-2(E),4( E)- heptadienoate (Compound A6, 29 mg, 0.08 mmol), in T11F (2 mL), MeOH (2 mL), was added aqueous LiOH (1M solution 0.4 ml) and the mixture was stirred for 24 hours at ambient temperature. The mixture was diluted with ether (80 mL), acidified with 10% HCl to pH 2, washed with water (5 mL) and brine (5 mL), dried and the solvent was removed by evaporation. The resulting crude material was purified by column chromatography to afford the title compound as a white solid.

[a] 21D +86.30 (c, 0.0015, CH2Cl2) Similar procedure of saponification conducted on the enantiomeric ester (-) ethyl 3,7-dimethyl-6(R),7(R)-methano-7(5,5,8,8- tetramethyl-5,6,7,8-tetrahydronaphth-2-yl) -2(E),4(E) -heptadienoate (Compound A8) yielded (-) 3,7-dimethyl-6(R),7(R)-methano-7(5,5,8,8- tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)-2(E),4(E)-heptadi enoic acid (Compound 2b).

[a]D21 -84.30 (c = .0015g/mL, CH2C12) HNMR (CDCl3) for both enantiomeric acids: 8 1.14-1.20 (m, 2H), 1.20 (s, 3H), 1.27 (s, 9H), 1.42 (s, 3H), 1.66, (s, 4H), 1.68-1.80 (m, 1H), 1.98 (s, 3H), 5.27 (dd, J = 9.9,15.4 Hz, 1H), 5.64 (s, 1H), 6.21 (d, J = 15.4 Hz, 1H), 7.03 (dd, J = 1.9, 8.1 Hz, 1H), 7.12 (d, J = 1.9 Hz, 1H), 7.24 (d, J = 8.1 Hz, 1H).